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Childhood vaccination coverage globally has increased since the launch of the Expanded 
Programme on Immunization in 1977 although delayed vaccination and failure to complete the 
recommended immunization series remains an important obstacle to the control vaccine-
preventable disease. In sub-Saharan Africa, where >50% of the world’s preventable deaths 
under-five years occur, research on the underlying mechanisms of under-vaccination is essential 
to realizing continued progress in eliminating preventable infectious disease-related morbidity 
and mortality in infants and young children. This dissertation explores drivers of vaccination 
disparities in sub-Saharan Africa, focusing on the competing programmatic priorities to innovate 
with inclusion of new vaccines while also urgently addressing under-vaccination against 
traditional disease targets. 
In aim I, we assessed the prevalence of delayed childhood vaccination and its relationship 
with under-vaccination in the first year of life, pooling Demographic and Health Survey data 
from 33 sub-Saharan African countries conducted between 2010 and 2018. High prevalence of 
delayed vaccination (>24%) was found for all doses in the schedule, indicating children were 
vaccinated >4 weeks after the target age for effective coverage. Delays were strongly associated 
with incomplete schedules including failure to receive one or more vaccine doses by 12 months 
of age. 
In aim 2, we examined the distal relationship between childhood death and immunization 
utilization patterns among surviving children. Using data from children and their decedent 
siblings across 33 SSA countries, we found that children with a prior decedent sibling had less 
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favorable vaccination outcomes compared to children who had no prior sibling death. Other 
measures of child mortality influence were considered at the province-level, which also showed 
less favorable vaccination outcomes for with surviving children in high U5M strata compared to 
lower ones.  
Finally, in aim 3, we evaluated the temporal trends in adherence to age-specific 
vaccination recommendations in two informal settlement communities in Nairobi, Kenya.  In this 
analysis, we compared trends between defined periods before and after the introduction of new 
vaccines in the basic immunization schedule using data from the longitudinal Nairobi Urban 
Health and Demographic Surveillance System between 2007 and 2015. We found no significant 
differences in the prevalence of delays between the two periods, suggesting no association 
between the introduction of new vaccines and the timeliness of delivering subsequent routine 
immunizations.  
Together, this dissertation examined perspectives not previously considered on how 
underlying mechanisms inherent to immunization program delivery and prioritization influence 
overall progress towards aspirational goals for achieving effective coverage. By combining 
multiple measures, these studies contribute new ways of monitoring the performance of 
immunization programs in low coverage countries and informing the design of strategies to 




Chapter 1 Introduction and Research Aims 
 
Routine immunizations are among the most ambitious and effective initiatives to have 
ever been implemented for improving child survival globally. 1–3 The Expanded Programme on 
Immunization (EPI), launched by the World Health Organization (WHO) in 1977 following the 
successful eradication of smallpox through mass immunization campaigns, has led to remarkable 
declines in the global incidence of many common vaccine preventable diseases including 
diphtheria, tetanus, pertussis, Hepatitis B, Haemophilus influenzae type B, and measles.4 Today, 
it is estimated that every year childhood vaccination prevents 2-3 million deaths worldwide and 
many more cases of illness and disability.5  Despite these successes for childhood survival, there 
remain challenges to extending the benefits of immunization to all children. Childhood 
vaccination coverage in sub-Saharan Africa (SSA) is the lowest of any World Health 
Organization (WHO) region6 while also experiencing the highest burden globally of under-five 
deaths associated with infectious causes, many of which are preventable with vaccination.7  
In years following EPI’s implementation in the WHO African region, the reach of 
immunization services increased from 5% coverage in 1980 to ≥50% of children receiving most 
commonly available vaccines by 2000.6,8 Between 2000-2015, coverage with the 3rd dose of 
diphtheria-Tetanus-Pertussis (Penta3), often used to monitor the performance of routine 
immunization services within and between countries, increased from 52 to 71%.6 However, in 
recent years, the pace of improvement has slowed or even reversed in some areas. By the end of 
2015, across the whole of the SSA, only Rwanda had met the regional goal of vaccinating at 
least 80% of infants with DPT3 in all districts while most other SSA countries exhibited 
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uniformly low coverage.9 In the following year, 2016, it was reported that 1 out of every 5 
children in the region went without receiving any recommended life-saving vaccines (i.e. was 
non-vaccinated).6 Additionally, survey-based research indicates that vaccination is often delayed 
for children who do have access to routine immunization services.10 This dissertation contributes 
new perspectives for improving the reach of basic immunization services in SSA by evaluating 
both completion and timeliness of recommended vaccines. The research uses data sources 
commonly employed for the study of vaccination uptake, including cross-sectional assessment of 
vaccination status based on home-based records and parental recall, as well as longitudinal 
surveillance platforms installed to monitor health conditions for highly vulnerable populations. 
The specific research aims, and their hypotheses explored are as follows: 
The first aim estimates the levels of delayed vaccination and under-vaccination across 33 
sub-Saharan African countries using child-level vaccination records collected by Demographic 
Health Surveys between 2010-2019. Vaccination status for children at each age-specific 
recommended interval in the basic vaccination schedule was ascertained to examine associations 
between dose-specific delays and overall completion of the schedule. The hypothesis for this aim 
was that children frequently experience delayed vaccination, well after the recommended ages, 
and that these dose-specific delays in vaccine receipt would result in a lower likelihood of 
completing the basic immunization schedule by 12 months of age.  
The second aim considers how the premature loss of a child under-five may influence 
vaccination patterns in other surviving children in the family and community by evaluating birth 
histories and vaccination records collected in Demographic and Health Surveys across 33 sub-
Saharan African countries. The underlying exploratory hypothesis was that families who 
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experience a child death would have improved vaccination outcomes in subsequent children 
compared to families who do not experience such a life event. 
The third aim examines whether the adoption of new vaccines, which add complexity to 
the basic schedule, shows any association with the timeliness of routine immunization services in 
two informal urban settlements in Nairobi, Kenya. Using data from the Nairobi Urban Health 
and Demographic Surveillance System, vaccination timeliness was evaluated over the period of 
2003-2015 and then compared between the pre-introduction and post-introduction phases of new 
vaccine adoption in the Kenyan Expanded Programme on Immunization (KEPI). Considering 
that new vaccines introduced in this period were recommended for co-administration with other 
vaccines in the routine schedule, the hypothesis was that no abrupt changes to the timeliness of 
vaccination would occur when comparing the levels of delayed vaccination in the pre- and post-
periods. 
Background 
The global landscape of immunization: challenges and opportunities in sub-Saharan Africa 
 
WHO, member countries, and global donor partners have supported a massive scale-up of 
immunization services over the past fifty years.11 With an estimated economic return of 16 times 
the required resource investment12, continued strengthening of immunization services in low 
resource settings has even become a strategy for poverty alleviation in addition to improving 
childhood survival.13,14 Since 1977, countries worldwide have used six basic antigens in their 
programs: Bacillus Calmette–Guérin (BCG), diphtheria-pertussis-tetanus (DPT), polio, and 
measles.11 The delivery of these six antigens widely has led to the establishment of a global 
platform for disease elimination and eradication programs such as those targeting measles and 
polio, as well as more routine control of other traditional vaccine-preventable diseases and 
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diseases for which new vaccines have been developed.11 The basic schedule of vaccines 
currently available to low- and middle-income countries has expanded to include vaccination 
against Hepatitis B, Haemophilus influenzae serotype B, rubella, mumps, pneumococcus, 
rotavirus, various meningococcus, and yellow fever in endemic areas.15  
Immunization as a childhood survival strategy was central to making global progress 
towards the Millennium Development Goal (MDG) 4, which aimed to reduce under-five 
mortality by two-thirds between 2000 and 2015.2 During these years, the Bill and Melinda Gates 
Foundation, governments, and other development assistance partners came together to establish 
Gavi, the Alliance, to help subsidize the introduction of new, costly vaccines and support 
modernization of outdated immunization delivery and vaccine storage systems in some of the 
world’s poorest countries.15 In parallel, WHO and its partners renewed ambitious goals for 
immunization programs with a major focus on both expanding the reach of immunization and the 
number of disease targets in the basic schedule through the Global Vaccine Action Plan (GVAP). 
The GVAP 2010-2020, endorsed by the World Health Assembly in 2012, sought to accelerate an 
equity agenda for immunization programs by calling on all countries worldwide to achieve 90% 
coverage with their programs at national level, and at least 80% coverage of all lower 
administrative reporting jurisdictions.16  
Many high-income countries had met or exceeded the GVAP goals by the 1990s and 
early 2000s. Today, the focus of programs in these countries has now shifted to coverage 
maintenance amid growing sentiments of vaccine hesitancy and even increased refusal despite 
overwhelming evidence in support of the benefits of vaccination for child health.16 By contrast, 
in sub-Saharan Africa and other lower-income regions, there was a substantial gap to close 
between the baseline reported vaccination coverage in 2010 and the aspirational goals proposed 
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for achievement during the decade.17 For example, at baseline, 33 of 44 sub-Saharan African 
countries needed to substantially improve coverage to meet the GVAP goals.6 Of these countries, 
17 were in a position of needing to scale-up coverage of their immunization programs by more 
than 15%.6 Over the past decade, while progress has been made in the sub-region, much of the 
incremental coverage improvements have stalled and, as of 2019, a number of countries remain 
‘off-track’ by 20% or more in their coverage to meet the end of decade goals.6,16,17 
For the global immunization agenda beyond 2020, ambitious plans are being discussed 
yet again to guide sub-Saharan African countries and others globally in the post-MDG era which 
is now framed by the Sustainable Development Goals (SDGs) 2030.13 Inequities in the provision 
of all available vaccines and access to complete coverage is at the center of these discussion, 
particularly in the face of population growth, increasing rates of migration and urbanization, and 
serious concerns for the capacity or political will of governments to halt the spread of emerging 
diseases with other control measures complimentary to vaccination.17 Under ideal 
implementation conditions, immunization systems would deliver all vaccines proven to be safe 
and effective to all children, and especially prioritizing any considered high-risk for vaccine-
preventable diseases.13 Although strict indicators for monitoring immunization performance are 
not made explicit in the newly proposed plans, there is an implicit emphasis on moving towards 
a measure of progress that helps identify under- and un-immunized populations and target 
interventions towards these populations to minimize their overall risk of vaccine-preventable 
disease acquisition and contribution to transmission.13  
Measures for monitoring the performance of immunization programs and their impact on health 
Vaccination coverage targets reflect assumptions about the proportion of individuals that 
would need to confer vaccine induced immunity to slow disease transmission and reduce the 
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overall burden of disease, otherwise known as the critical vaccination or herd immunity 
threshold.18 While the exact threshold level depends on whether the goal is disease reduction or 
elimination, many geographic regions have adopted a vaccination coverage target that aligns 
with levels thought to be required for interrupting indigenous transmission of measles.19 Measles 
is a highly contagious virus that is cited as resulting in 12-18 additional secondary cases per 
infection in a fully susceptible population.20 Under these conditions, defined by transmission and 
contact rates, population immunity of 91-94% would be required to prevent the occurrence of 
secondary chains of transmission.20 Achieving vaccination coverage at these levels and then 
sustaining it over time has proven to be an implausible goal for many settings during the 
implementation of the GVAP.17 Instead, combining multiple measures to track the performance 
of immunization systems provides a better understanding of where and how to target resources 
and interventions, that may eventually lead to attaining the aspirational coverage goals at higher 
levels for disease control and elimination. This type of monitoring involves measurement of 
access, retention, and adherence over the course of the childhood immunization schedule at 
sufficiently granular levels of analysis to detect risk pooling.21  
Childhood vaccination schedules in sub-Saharan Africa include, at minimum, 
administration of Bacillus Calmette-Guerin (BCG) at birth for the prevention of Tuberculosis; 
Pentavalent (Penta, or the 5-in-1 combination of Diphtheria-whole cell Pertussis-Tetanus 
[DwPT] + Haemophilus influenzae type B [Hib] + Hepatitis B [HepB]) and polio vaccines at 6, 
10, and 14 weeks of age to prevent against the debilitating health impact of polio, Hib-associated 
disease, whooping cough, neonatal tetanus, and the acute and long-term effects of infancy 
acquired Hepatitis B; and at least one dose of Measles vaccine at 9 months age.22–29  
Additionally, vaccines to prevent rotavirus diarrheas and pneumococcal disease in young infants 
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have been available for some time now have been developed and adopted for routine use in the 
majority of SSA nations between 2005 and present.15 These vaccines are administered 
concomitantly with other vaccines at 6, 10 and 14 weeks.30,31  
Access to immunization is often defined as receipt of BCG at birth as the initial vaccine 
recommended in childhood schedules. Subsequently, in follow-up immunization visits, retention 
is evaluated by considering any missed doses over the course of a multi-dose series, i.e. doses 1, 
2, and 3 of polio and pentavalent vaccines. Finally, adherence to specific timing intervals for 
vaccination is useful for more precisely predicting age-specific vaccination coverage and, by 
proxy, immunity and protection. Together, these measures provide a framework for estimating 
the effective level of coverage of the full immunization schedule, or the proportion of children 
who receive all vaccines according to recommendations and are therefore considered protected 
against the disease targets included in the local schedule.32 
Methods and data sources for tracking immunization progress in SSA 
The measures previously reviewed are often calculated from administrative reporting at 
health facilities and then aggregated up to higher jurisdictions to estimate vaccination coverage 
at varying levels: sub-national, national, regional, and global.21 Using routine health information 
systems, these estimations often rely on consolidating paper-based report of the number of 
vaccines administered to any child in a given time period as the numerator, divided by the 
estimated target population for the reporting jurisdiction over the same period (i.e., number of 
live births).21  The use of administrative reporting for the estimation of vaccination coverage can 
lead to substantial over-assurance of the assumed level of protection in the population if the 
denominator is under-estimated, which is a concern where birth registration is low or vital 
records systems do not have complete coverage of births and accurate capture of migration.33 
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The limited validity of these estimates is often apparent when reported as coverage of greater 
than 100%.34 Another source of over-stating assumed protection is counting children older than 1 
year of age in the numerator even though they were vaccinated well beyond the target age for 
coverage and protection.21,33 While under-estimation of coverage is less of a concern for disease 
control implications, there are consequences for misallocating resources to areas that do not truly 
represent high-need or high-risk when these resources could be more useful elsewhere.  
Recognizing limitations regarding administrative data, many immunization program 
managers and policymakers rely on survey-based research to track the individual child-level 
status of vaccination receipt, either longitudinally in small populations or cross-sectionally across 
larger populations at different time intervals.33 Among the several surveys used to collect 
vaccination histories, the Demographic Health Surveys (DHS) and Multiple Indicator Cluster 
Surveys (MICS) are the most commonly used by countries and the WHO to validate or inform 
judgements about the quality of administrative reporting.35 These survey programs use a multi-
stage probability sampling scheme of households to estimate nationally representative health and 
demographic indicators. Of importance for cross-national benchmarking studies to evaluate 
progress towards regional or global health goals, these surveys are standardized in their design 
and implementation between countries.36   
DHS has broader availability in sub-Saharan Africa than MICS for estimating 
vaccination outcomes and was used in the first two aims of this dissertation. Another source of 
emerging importance for estimating or validating measures for tracking immunization 
performance locally is the 40+ health and demographic surveillance sites (DHSS) established 
throughout urban and rural areas in several countries of sub-Saharan Africa.37 These systems aim 
to provide timely data for health policy and decision-making in places where civil and vital 
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registries are lacking or weak by establishing continuous monitoring of births and deaths at a 
more local level than the government systems currently in place.   One such DHSS was 
established in two informal urban settlement communities outside Nairobi, Kenya in 2002.38 The 
African Population and Health Research Center (APHRC), based in Nairobi, Kenya, manages 
the system that has now tracked births, migration, and deaths in the Nairobi neighborhoods of 
Korogocho and Viwandani for nearly two decades.39 This system, the Nairobi Urban Health and 
Demographic Surveillance System (NUHDSS), was used as the primary data source for the third 
aim of this dissertation. 
Both the cross-sectional survey approach managed by DHS and the longitudinal 
surveillance project managed by APHRC collect information on vaccination histories for 
children under the age of five in all households included in their sample or census tracking, 
respectively. Using a combination of parental recall probing and review of home-based records, 
survey interviewers collect the status of receipt for each recommended vaccine dose in the basic 
immunization schedule, the date on which vaccine administration occurred, if available, and 
other data to characterize children and their caretakers.40,41 These data sources have previously 
been used to describe vaccination timeliness and coverage of specific doses and the complete 
vaccination schedule, as well as evaluate child, caretaker, and community factors that are 
associated with vaccination outcomes in several settings in SSA.42,43,52–54,44–51  
Barriers to improving timing and completion of immunization in children 
Studying factors that characterize childhood vaccination outcomes has been a major 
focus of the research literature on immunization services, as evidenced by the number of 
published reviews of the peer-reviewed literature on the subject in low- and middle-income 
countries.32,55–57 A recent systematic review of 48 peer-reviewed studies on the barriers to 
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childhood immunization in sub-Saharan Africa found a common set of both modifiable and non-
modifiable factors repeatedly at the center of this literature.58 Parental and provider knowledge 
gaps regarding the safety and effectiveness of vaccines, lack of caretaker trust in the health 
system, and limited access to short wait times or convenient vaccination clinic hours were among 
the most commonly identified barriers to vaccination when considering factors that could be 
modified with community education and outreach.58 Other child, mother, and community factors 
were also commonly explored such as education, race/ethnicity, religious affiliation, household 
wealth, population density, child rank, and household living arrangements.58  
Identifying factors that positively or negatively predict vaccination uptake is helpful for 
developing priority groups for strategic outreach, but often these studies have recycled the same 
set of known risk factors instead of (1) looking more closely at bottlenecks in the system, or (2) 
considering overlapping factors that drive disparities in coverage. This dissertation explores three 
themes that were identified as gaps in the literature on barriers to childhood immunization in 
SSA, with a particular focus on using multiple measures of immunization performance to more 
closely ascertain the potential effective coverage of immunization services and therefore impact 
on child health outcomes. First, the timeliness and completion of the basic immunization 
schedule is assessed in 33 SSA countries. These two measures of the performance of 
immunization services are evaluated jointly with the aim of determining the extent to which 
delayed or late vaccination is associated with overall completion rates. Timeliness and overall 
completion are two important measures for evaluating the performance of immunization 
programs and approximating the impact of immunization on child health. However, the research 
literature has treated them as separate areas of focus instead of two measures that are intrinsically 
linked.  In a second research aim of this dissertation, risk-prioritization for targeting 
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immunization outreach activities, special campaigns, and educational resources is evaluated 
considering the experience of childhood death in families and communities. Previous research on 
the determinants of under-vaccination in children has not explored the effect of overlapping 
disadvantages experienced among families and communities who reside in areas that are 
characterized by low access to health services and high under-five mortality. This second aim 
considers how experiences with under-five death in the family and community influence 
vaccination patterns in their surviving children in the same 33 SSA included for the first aim. 
Finally, the third research aim examines whether innovation to the basic immunization schedule, 
by adding additional vaccines and expanding the number of disease targets for control of VPDs, 
has had any negative implications for the timeliness of routine immunization. Using the example 
of pneumococcal conjugate vaccine (PCV) introduction in Kenya, the timeliness of routine 
immunization was assessed before and after the adoption of PCV in two urban, poor 
communities in Nairobi. Together, the findings from these three research aims provide new 
perspectives on how the use of multiple measures of immunization performance could help re-
focus resources to improve vaccination outcomes and child health in SSA.  
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Introduction: Improving the timeliness and completion of vaccination is key to reducing under-
5 childhood mortality. This study examines the prevalence of delayed vaccination for doses 
administered at birth and age 6 weeks, 10 weeks, 14 weeks and 9 months and its association with 
under-vaccination among infants in sub-Saharan Africa. 
Methods: Pooling data across 33 sub-Saharan Africa countries, vaccination timing and series 
completion was assessed for children aged 12–35 months who were included in the 
immunization module of the Demographic and Health Surveys conducted between 2010 and 
2019. Survey design–adjusted logistic regression modeled likelihood of not fully completing the 
basic immunization schedule associated with dose-specific delays in vaccination. Data were 
obtained and analyzed in May 2020. 
Results: Among children with complete date records (n=70,006), the proportion of children 
vaccinated with delays by ≥1 month was high: 25.9% for Bacillus Calmette–Guérin (birth); 
49.1% for the third dose of pentavalent (14 weeks) and 63.9% for the first dose of measles (9 
months) vaccines. Late vaccination was more common for children born to mothers with lower 
levels of educational attainment (p<0.001) and wealth (p<0.001). Controlling for place, time, and 
sociodemographics, vaccination delays at any dose were significantly associated with not 
completing the immunization schedule by 12 months (Bacillus Calmette–Guérin: AOR=1.93, 
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95% CI=1.83, 2.02; pentavalent: AOR=1.50, 95% CI=1.35, 1.64; measles: AOR=3.76, 95% 
CI=3.37, 4.15). 
Conclusions: Timely initiation of vaccination could contribute to higher rates of complete 
immunization schedules, improving the reach and impact of vaccination programs on child 
health outcomes in sub-Saharan Africa. 
 Introduction 
Considerable progress has been made in reducing under-5 mortality, which globally has 
declined by 53% from 1990 to 2015.1 Despite this success, progress in sub-Saharan Africa (SSA) 
has been slower: Only 8 of 43 countries in the region met or exceeded the Millennium 
Development Goals related to childhood survival by 2015.2 Consequently, it is estimated that 
nearly two thirds of SSA countries will need to accelerate improvement in order to achieve the 
updated goal of reducing under-5 mortality to <25 deaths per 1,000 live births in every country 
by 2030 in line with the Sustainable Development Goals.1 
Inequities in vaccination are a major contributor to disparities in childhood health and 
survival.3,4 This is evidenced in SSA, where some of the highest rates of childhood mortality 
globally (>100 per 1,000 live births) coincide with less than one third of countries reporting 
immunization schedule completion in infants >60%.5 The low rates of age-appropriate 
vaccination directly threaten progress made in the control and elimination of vaccine-preventable 
diseases (VPDs) that contribute importantly to improving childhood survival.6,7 The WHO 
Expanded Programme on Immunization recommends that young children in most countries 
globally receive 1 dose of Bacillus Calmette–Guérin (BCG) at birth, 3 doses of oral polio 
vaccine (polio) and 3 doses of the pentavalent (penta) combination vaccine (i.e., diptheria-
tetanus-pertusis, hepatitis B, Haemophilus influenzae type b) at age 6 weeks, 10 weeks, and 14 
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weeks and 1 dose of measles-containing vaccine (measles) at age 9 months.8 These 
recommendations are adapted to address the specific epidemiological profile at the country level, 
but all countries in SSA at a minimum use this basic series and some may additionally offer 
newer childhood vaccines. To achieve effective control of VPDs, high rates of both timely 
receipt and completion of the basic schedule are needed. In acknowledgement of this, the 
WHO’s Immunization Agenda 2030, which has put forth aspirational goals for national 
immunization programs in line with the Sustainable Development Goal agenda, underscores the 
importance of both receiving vaccination altogether but also ensuring that access to on-time 
vaccination is available to target the age-specific vulnerabilities children have for each VPD 
covered in the schedule.9 
Previous studies on timeliness and completion of childhood vaccination in SSA have 
focused on underlying determinants, including spatial and sociodemographic factors associated 
with low uptake or poor adherence to age-specific vaccination recommendations.10–15 However, 
no studies have evaluated the association between delayed vaccination and failure to complete 
the basic series by 12 months outside of high-income countries.16,17 Delayed vaccination poses 
public health risks both in terms of disease acquisition for the individual as well as transmission 
in the community as children remain susceptible to and reservoirs for VPDs for unnecessarily 
prolonged periods of time.18,19 In real time, the level and duration of risk associated with delayed 
vaccination is unknown because the visibility of vaccination timing is limited when relying on 
administrative data.7 Across countries, vaccination coverage is estimated by aggregating reported 
administrative data on the total doses administered for each vaccine in the target population of 
surviving infants, estimated from census data, over a defined period of time.20 These aggregate 
measures of coverage mask age-specific vulnerabilities, and potentially obscure patterns of 
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clustered risk that program managers and policymakers could address with a more granular view 
of adherence to age-specific vaccination recommendations.7 Importantly, although a less 
commonly explored implication, vaccination delays may also increase the likelihood of missing 
subsequent doses, and even dropping out of the schedule before concluding the full series of 
vaccines in the first year of life, as is recommended. Understanding the extent to which vaccine 
delays occur across the schedule and defining the role that delayed vaccination plays in 
completing all recommended vaccines could help inform strategies that reduce bottlenecks to 
achieving full coverage of the childhood vaccination schedule, ultimately improving the 
effectiveness of vaccination and its impact on childhood survival. Using data from the 
Demographic Health Survey (DHS) conducted in 33 SSA countries, this study seeks to: (1) 
estimate the prevalence of delayed vaccination at specific vaccination encounters in the schedule 
and (2) explore the association between delays in dose-specific vaccination and the completion 




Established in 1984, the DHS program collects nationally representative data on health 
and demographics using standardized survey designs across participating countries.21 This 
widely used cross-sectional data source has been described in depth elsewhere.22 All publicly 
accessible DHS surveys in SSA conducted between 2010 and 2019 were identified for this study, 
totaling 47 surveys from 33 countries (available as of June 2020 at 
www.dhsprogram.com/data/available-datasets.cfm). The sample was restricted to the most recent 
survey conducted per country (Table 2.1). 
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The DHS uses a multistage, unequal probability sampling scheme to identify a nationally 
representative sample of households.22 At the first stage, household clusters are selected based on 
probability proportional to the population area size from each rural or urban strata, defined by the 
host country. Then, after creating a complete listing of households within the cluster, 
approximately 30 households are randomly sampled. All women aged 15–49 years who reside in 
the selected households are invited to participate in the survey.23 
Vaccination data are collected for living children who were born in the 3–5 years prior to 
the interview.24 Data from children aged 12–35 months at the time of interview were used in this 
study, as this age group consistently participated in the vaccination module across the countries 
selected for inclusion. Owing to the potential of correlated vaccination patterns among siblings, 
the sample was restricted to the youngest child in instances where multiple children from the 
same family were age eligible (excluding 3.2% of the age-eligible sample). 
Mothers are asked to report on their children’s status of receipt for each recommended 
vaccine in the national immunization schedule. To verify, interviewers review family health 
cards or children’s immunization records, when available, to confirm the date of vaccination.25 
Dates recorded on the vaccination card were used to assess timeliness and series completion. 
Children who did not have a card available at the time of interview or who had a card without 
record of complete or plausible vaccination dates were excluded from analysis. 
 
Measures 
The primary outcome of interest was completion of the recommended immunization 
schedule in the first year of life. All analyses used complete vaccination series status as the 
reference level. Incomplete vaccination schedules were defined as lacking any dose in the 8 basic 
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dose series, which includes BCG at birth, 3 doses each of penta and polio at age 6, 10, and 14 
weeks, respectively, and 1 dose of measles at age 9 months. Dose-specific vaccination timeliness 
was explored by creating a 3-way categorization that reflects adherence or non-adherence to the 
age-specific recommendations for each dose.9 Doses administered were defined as “on-time,” 
“delayed, as a first instance” of delayed vaccination in the schedule, or “delayed, with prior 
instances” of delay at prior vaccination encounters. Any dose that was recorded as having been 
administered ≥4 after the recommended age was considered delayed. Age (in days) at 
vaccination was used as the cut off for on-time versus delayed vaccination, and history of 
delayed vaccination any prior dose was used to assign children to “delayed, with prior instances” 
(Table 2.2). 
Age in days at vaccination was calculated by subtracting the child’s birthdate from the 
vaccination date recorded on a child’s immunization card. Where month or year of birth were 
missing, other available dates in the survey were cross-referenced to define plausibility bounds. 
For cases in which the day of birth was missing but the date of BCG vaccination complete 
(n=14,243), age at vaccination was imputed drawing from the distribution of known values for 
age at BCG vaccination and then birthdate was back-calculated by subtracting the imputed age in 
days from the date at BCG vaccination. 
 
Known predictors of vaccination timeliness and completion were also explored and used as 
covariates in analysis. Birth setting was defined as: institutional delivery in public sector setting. 
institutional delivery in private sector setting, non-institutional delivery with presence of skilled 
healthcare attendant, non-institutional delivery with traditional birth attendant, or non-
institutional delivery with no assistance. Child’s rank in the birth order, adjusting for multiple 
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births, was also considered. Missed opportunity for co-administration was assessed using a 
dichotomous variable for each of the 3 instances where Penta and polio co-administration should 
occur. Maternal educational attainment, parental marital status, household wealth, and residence 
location were assessed using the categorical definitions defined by DHS.26 
 
Statistical Analysis 
Delayed vaccination across levels of child characteristics was assessed and significance 
of differences evaluated. Using multinomial logistic regression, predictors were evaluated for 
categories of dose-specific delayed vaccination: (1) delayed, first instance versus on-time and (2) 
delayed, prior instance versus on-time. Then, the primary association of interest was explored, 
separately evaluating the association between delayed receipt of BCG, Penta1, Penta2, Penta3, 
and measles and schedule completion in a set of logistic regression models that included children 
conditional on having received the vaccine. ORs, average marginal effects and predicted 
probabilities of the outcome were estimated for first instance of delayed vaccination and repeated 
delays in vaccination. Average marginal effects and predicted probabilities of the outcome allow 
for making more appropriate comparisons across models due to failing to assume that 
unobserved heterogeneity is the same across model samples conditional on having received a 
vaccine, such as children who receive BCG differ from children who receive doses later in the 
schedule. Covariates that were identified as significantly associated with vaccination delays were 
retained for controls in the adjusted models exploring associations between dose-specific delays 
and schedule completion. Necessitating a control for time and place in the multi-country models, 
indicator dummy variables for each country and continuous variables for year and child’s age at 
interview were used. As a sensitivity analysis, country-stratified models were used to evaluate 
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the heterogeneity in effects across countries in the sample. All analyses used country-specific 
sampling weights and survey design strata variables to account for the complex sample design. 
Unweighted case frequencies and weighted proportions are reported. All analyses were 
conducted in Stata, version 16.1. 
Results 
A total of 136,745 children aged 12–35 months were surveyed in the most recent DHS 
waves during 2010–2019 across the 33 included countries. After selecting the youngest child 
from households with multiple age-eligible children, the availability of vaccination records in 
132,405 children was assessed. Across country surveys, the median proportion of age-eligible 
children who had a vaccination card available during the interview was 58% (IQR=46%–63%). 
In total, 61,399 age-eligible children were excluded (Table 2.3), owing either to having no 
vaccination card available (n=53,659) or implausible/missing vaccination dates sporadically 
throughout their records (n=8,740). Although characteristics of children stratified on the 
restriction criteria did not differ substantially between groups, the analytic sample (n=70,006) 
represented children who had considerably higher rates of vaccination schedule completion 
overall at the time of interview than children excluded from analysis (Table 2.3). 
In terms of under-vaccination in the sample, the proportion of children missing 
recommended doses or receiving delayed doses increased with each subsequent visit across the 
vaccination milestone visits, using BCG, penta1–3, and measles vaccination status as 
representative of the 5 vaccine administration encounters across the schedule as penta1–3 are 
administered concomitantly with polio1–3 (Figure 2-1). Though <1% of children received no 
vaccines in their first year of life, the other 20% of children who did not complete their schedule 
by age 12 months had missed an important number of doses when considering the full 8-dose 
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recommended series: 5% missing 4–7 doses, 6% missing 2–3 doses, and 9% missing ≥1 dose 
(country-specific estimates are in Table 2.1). 
 
Among vaccinated children across countries, late administration by ≥4 weeks was: 25.9% 
for BCG; 23.5% for the first, 38.2% for the second, and 49.1% for the third doses of Penta; and 
63.6% for measles (Table 2.4). The proportion of children receiving delayed vaccination 
repeatedly across the schedule was consistently highest for higher birth order (7+) children or 
those who were born in non-institutional settings with no skilled assistance. By contrast, the 
proportion of delayed vaccination trended substantially lower for children born to mothers with 
higher levels of educational attainment and household wealth. For example, in the wealthiest 
households, only 35.3% of children were delayed for Penta3 vaccination compared with 58.7% 
in the poorest households. Similarly, there was more than a significant difference in the 
prevalence of delayed Penta3 vaccination between children of mothers who had high educational 
attainment (24.4%) versus no education (60.8%). For children who were vaccinated against 
measles, the proportion affected by delays did not vary as substantially across childhood and 
maternal predictors as was observed for other vaccination delays. Nonetheless, except for 
parental marital status and child sex, all sociodemographic characteristics demonstrated some 
level of significant association with delayed vaccination, either as a first instance or following 
prior delays (p<0.05) (Table 2.6). 
Children with delayed vaccination were at increased odds of not finishing their schedules 
by age 12 months compared with children who received on-time vaccination (Table 2.5). The 
magnitude of this association was large for children who received delayed vaccination against 
measles as the first occurrence of delay in the schedule (AOR=3.76, 95% CI=3.37, 4.15) or 
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following a pattern of delayed vaccination across the schedule (AOR=8.21, 95% CI=7.50, 8.91) 
compared with on-time vaccination in children. However, children who were both delayed in 
receiving measles and did not complete their schedules by age 12 months often did finish their 
schedules at an older age. The median age of measles vaccination for these children was 4.25 
months after the recommended age (13.25 months), resulting in their under-vaccination status at 
age 12 months. 
Patterns of repeated delays across the childhood schedule resulted in a significantly 
higher probability (p<0.001) of drop-off from the recommended series compared with children 
who were receiving on-time vaccination (Penta1 delay with prior delays: 21.2% higher; measles 
delay with prior delays: 21.5% higher) (Table 2.5). Both “first instance” delays and “with prior” 
delays at the first dose of Penta significantly predicted incompletion rates, which were sustained 
for delays at Penta2, Penta3, and measles, though with predictions of the probability of 
incompletion declining with each subsequent dose (Figure 2-2). In the country-stratified models 
explored as a sensitivity analysis, there was variation across countries in the magnitude of 
association between dose-specific delays and not finishing the basic childhood vaccination 
schedule (Supplemental Figures 2-1, 2-2, and 2-3). However, children with vaccination delays in 
≥1 dose compared with on-time doses consistently showed a higher probability of not 
completing the schedule. 
 
Discussion 
Assessment of vaccination timeliness is essential to identifying age-specific risks of 
VPDs, which continue to contribute to under-5 mortality in SSA.27,28 Similarly, defining the role 
that delayed vaccination plays in hindering the completion of the recommended schedule in the 
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first year of life is needed for evidencing the value of programmatic interventions that target 
timely vaccination as a means to improving protective coverage overall. Although uptake of 
individual vaccine doses has improved (i.e., Penta3 increased from 77% to 81% in Eastern and 
Southern Africa and 65% to 70% in West and Central Africa during 2010–2019), aggregate 
measures of coverage are an imprecise predictor of the population risk profile for VPDs. These 
measures do not account for the timing of vaccination and the resulting age-specific protection, 
or lack thereof when delays lead to additional delays, or eventual dropout and under-
vaccination.29 This study explored the association between children having dose-specific delays 
and completing their immunization schedules before age 12 months. Using recent nationally 
representative survey data from 33 SSA nations, the findings suggest that dose-specific delays 
are common and that those delays lead to a significantly higher probability of dropping off the 
schedule, resulting in prolonged susceptibility to specific VPDs beyond the first year of life. 
To the authors’ knowledge, previous studies on the determinants of under-vaccination in 
SSA have not considered the role of adherence to age-specific vaccination recommendations, 
besides on-time vaccination at birth. Studies in both low- and higher-income settings alike have 
found that the risk of programmatic dropout associated with delayed initiation of vaccination at 
birth is significant.16,17,30 In this study, delayed administration of any dose was significantly 
associated with an increased likelihood of not completing the immunization schedule during the 
first year of life. Across immunization programs in SSA, education and outreach designed to 
improve community demand for on-time vaccination services could lessen the programmatic 
burden of follow-up when children fall behind in their schedules and reduce the resulting risk of 
under-vaccination. However, vaccine stock-outs and other service disruptions are often 
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unavoidable barriers to access. In these scenarios, outreach and catch-up campaigns remain 
important for bringing children up-to-date on their vaccination. 
It is worth clarifying that some delays may result from intentional adjustments to the 
schedule for individual children following delayed initiation of a multi-dose series. This is 
because a 4-week interval is recommended between doses to avoid blunting the immune 
response.8 Nonetheless, across countries, delays were predictive of subsequent delays that 
extended beyond the minimum recommended interval between doses, and even predictive of 
dropout, both of which can contribute to under-vaccination after the first year of life. For 
example, instead of using the minimum interval required, 88% and 86% of delayed Penta2 and 
Penta3 vaccination, respectively, occurred >4 weeks after delayed receipt of the previous dose in 
the series. 
Consistent with immunization research in SSA,14,15,31–33 delayed vaccination observed 
across countries was most prevalent among families with socioeconomic and educational 
disadvantages. Although, notably, the prevalence of delayed measles vaccination as a first 
instance of delay did not differ as substantially across wealth and maternal education as 
compared to the variation across socioeconomic group observed for delayed doses earlier in the 
schedule. Instead, there were consistently high levels of delay for receipt of measles (>60%). 
Since the launch of the Expanded Programme on Immunization in 1979, countries have 
measured the success of their immunization programs by the coverage achieved with Penta3. 
Using administrative coverage of Penta3, immunization program performance may appear to be 
improving, yet when delays result in under-vaccination against measles, which currently is not 
tracked at a global level, the threat of a measles resurgence becomes an important concern and 
one that has come to recent fruition in a number of SSA countries.34 
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Considering existing challenges to reducing under-vaccination in the context of the 
destabilizing threat that pandemic spread of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) poses for weak public health systems, immunization programs must consider 
how to prioritize timely vaccination throughout the course of the schedule to ensure age-specific 
protection and to increase the likelihood of completing all recommended vaccines. Although 
standard outreach activities may not be feasible, continued emphasis on education for mothers 
and providers about the contingency plans for completing their infants’ immunization schedules, 
either through campaigns or health facility visits, will be needed. Where substantial concern for 
interrupted immunization activity may exist,35 immunization programs could also consider 
vaccinating against measles at younger infant ages in settings that warrant such an approach.8 
 
Limitations 
Despite contributing a new perspective on vaccination timeliness and under-vaccination 
in SSA, the approach and data sources used to study this association have some limitations. 
Children were excluded if they lacked complete vaccination histories, including those who had 
died prior to the interview. Both subpopulations likely differ substantially in their overall health, 
risk factors, and access to immunization from surviving children with complete records, which 
limits the generalizability of this study. Assuming that delayed vaccination is correlated with 
access to services and availability of a vaccination card is an indicator of access, it might also be 
assumed that delayed vaccination and dropout may even more frequently occur in children who 
do not have records. This would lead to underestimating the prevalence of vaccination delays 
and their contribution to overall completion rates. On the other hand, in the absence of electronic 
immunization registries, this study may have incorrectly classified vaccination outcomes if dates 
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were not correct or administered doses were not documented. Though, data quality measures are 
embedded in the DHS program to change implausible dates to missing and survey data are 
generally considered the gold standard for assessing immunization uptake.36,37 Although the 
surveys are cross-sectional, the availability of vaccination dates for the sample allowed the 
authors to establish the sequential timing of vaccine administration across the schedule and 
temporally associate delays, classified as a first-time delay or prior delays, with vaccination 
schedule completion as the ultimate outcome in the timing sequence. Finally, programming 
constraints and barriers to access predictive of under-vaccination undoubtedly vary across 
countries in SSA. Though the heterogeneity in the magnitude and direction of the main effects 
across countries was explored, identifying and adjusting for country-specific observed and 
unobserved confounding was outside the scope of this research aim to generally establish delays 
as predictive of overall vaccination status in SSA. Future studies on the country-specific nuances 
of each program could contribute more precise recommendations on how to intervene in cases 
where clear patterns of bottlenecks in schedule completion arise due to dose-specific delays. 
 
Conclusions 
This study identified delayed vaccination at birth and delays in subsequent doses as 
important impediments to completing the routine schedule in SSA. Although children in SSA 
who have contact with the immunization program likely have higher probability of survival 
associated with general health services access, the benefit of on-time and full immunization of 
individuals extends beyond the individuals themselves. Targeting on-time delivery of vaccines 
across the immunization schedule among individuals and communities may contribute to 




Table 2.1 Countries and sample sizes covered in Demographic Health Surveys (DHS) in the region of sub-Saharan Africa from 2010-2019 








% under-vaccinated  
by 12 months  
(study outcome) 
% under-vaccinated by 12 
months,  
by number of doses missing 
      
1 2 3-7 
8 
(all) 
Angola 2015-16 7 5524 1798 46% 12% 3% 24% 7% 
Burkina Faso 2010 6 5467 4076 16% 9% 1% 5% 0% 
Benin 2017-18 7 4865 3066 32% 15% 1% 13% 4% 
Burundi 2016-17 7 4980 3128 12% 9% 1% 2% 0% 
Congo Dem. 
Republic 
2013-14 6 6858 729 23% 12% 1% 9% 2% 
Congo 2011-12 6 3569 1300 36% 11% 5% 20% 0% 
Cote D'Ivoire 2011-12 6 2841 1547 45% 21% 2% 18% 4% 
Cameroon 2011 6 4361 1995 28% 14% 2% 10% 2% 
Ethiopia 2016 7 3855 1647 43% 20% 4% 15% 3% 
Gabon 2012 6 2344 1250 73% 11% 8% 54% 1% 
Ghana 2014 6 2262 1770 19% 13% 2% 4% 0% 
Gambia 2013 6 3133 2474 24% 16% 3% 5% 0% 
Guinea 2018 7 2677 1307 70% 23% 2% 28% 17% 
Kenya 2014 6 8068 5068 23% 16% 2% 4% 0% 
Comoros  2012 6 1210 640 33% 16% 3% 13% 1% 
Liberia 2013 6 2709 1107 33% 16% 2% 15% 1% 
Lesotho 2014 6 1228 857 26% 16% 4% 5% 0% 
Mali 2018 7 3675 1396 38% 21% 3% 12% 1% 
Malawi 2015-16 7 6500 4053 22% 16% 2% 3% 1% 
Mozambique 2011 6 4233 2894 36% 17% 4% 13% 2% 
Nigeria 2018 7 11893 3515 42% 19% 3% 18% 3% 
Niger 2012 6 4525 2178 38% 21% 3% 13% 2% 
Namibia 2013 6 1973 1077 18% 11% 2% 5% 0% 
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Rwanda 2014-15 6 3070 2437 30% 29% 0% 1% 0% 
Sierra Leon 2013 6 4096 2573 33% 18% 1% 12% 1% 
Senegal 2017 7 4616 2833 22% 14% 2% 5% 1% 
Chad 2014-15 6 6200 897 57% 13% 4% 30% 9% 
Togo 2013-14 6 2678 1579 29% 19% 1% 9% 0% 
Tanzania 2015-16 7 4034 2731 24% 15% 2% 6% 1% 
Uganda 2016 7 5838 3392 36% 20% 5% 11% 1% 
South Africa 2016 7 1346 632 22% 15% 4% 4% 0% 
Zambia 2018-19 7 3811 2397 20% 14% 2% 3% 0% 
Zimbabwe 2015 7 2307 1663 21% 14% 3% 4% 0% 
 
         
Median   3855 1798 30% 16% 2% 10% 1% 
First Quartile   1210 1300 22% 13% 2% 5% 0% 
Third 
Quartile 
  4980 2833 38% 19% 3% 15% 2% 
Total  
(% mean) 
  136746 70006 31% 16% 2% 11% 2% 
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Table 2.2 Age-specific recommendations for the basic immunization schedule endorsed by WHO 
Age at 
administration 
Vaccines Minimum acceptable 
age (days) 




0 days Greater or equal to 28 days 
6 [8] weeks  Penta1, 
OPV1 
42 [56] days Greater than 70 [84] days  
10 [12/16] weeks Penta2, 
OPV2 
Age in days at previous 
dose + 28 
Greater than 98 [112/140] 
days 
14 [16/24] weeks Penta3, 
OPV3 
Age in days at previous 
dose + 28 
Greater than 126 [140/196] 
days 
9 months Measles 252 days Greater than 280 days 
 






Table 2.3 Characteristics of children 12-35 months according to data availability for assessing 













Child’s age 70,006 8,740 53,659 132,405 
  12-23 months 50% 50% 50% 50% 
  24-35 months 50% 50% 50% 50% 
Child’s sex 70,006 8,740 53,659 132,405 
  Male 57% 55% 45% 52% 
  Female 43% 45% 55% 48% 
Birth order 70,006 8,740 53,659 132,405 
  1st 23% 22% 22% 23% 
75%  2nd to 3rd 37% 36% 34% 36% 
  4th to 5th 29% 29% 30% 29% 
  6th + 11% 13% 14% 12% 
Birth setting 69,180 8,616 53,049 130,845 
  Institutional, public 66% 61% 50% 59% 
  Institutional, private 9% 8% 8% 9% 
  Home, skilled attendant 2% 3% 3% 2% 
  Home, traditional attendant 21% 25% 34% 26% 
  Home, no attendant 3% 3% 5% 4% 
Vaccination status,  
according to card or recall 70,006 8,740 53,659 132,405 
  Fully vaccinated 21% 26% 78% 43% 
  Not fully vaccinated 79% 74% 22% 57% 
Maternal age (at child's 
birth) 
70,006 8,740 53,659 132,405 
  Under 19 15% 17% 18% 16% 
  20-29 52% 52% 52% 52% 
  30-39 29% 28% 26% 28% 
  40-49 4% 4% 4% 4% 
Maternal education 69,995 8,739 53,655 132,389 
  None 36% 37% 44% 39% 
  Primary 34% 35% 29% 32% 
  Secondary 27% 25% 24% 25% 
  Higher 3% 3% 3% 3% 
Household wealth quint. 70,006 8,389 53,659 132,405 
  Poorest 20% 22% 25% 22% 
  Poorer 21% 22% 22% 22% 
  Middle 21% 21% 19% 20% 
  Richer 20% 19% 18% 19% 
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  Richest  18% 16% 15% 17% 
Place of residence 70,006 8,389 53,659 132,405 
Urban 34% 34% 33% 34% 
















1st dose  
(Birth) (6 or 8 wk) (10, 12 or 16 wk) (14, 16 or 24 wk) (9 mo.) 
 % pe % pe % pe % pe % pe  
          
Overall c 25.9%  23.5%  38.2%  49.1%  63.6%  
Child's sex  0.33  0.24  0.46  0.51  0.23 
  Male 25.7%  24.9%  38.4%  49.3%  63.9%  
  Female 26.1%  25.4%  38.0%  49.0%  63.3%  
Child's age (at interview)  0.20  0.61  0.05  0.02  0.01 
  12-23 months 25.7%  25.1%  37.8%  48.6%  62.8%  
  24-35 months 26.2%  25.3%  38.8%  49.9%  64.6%  
Birth order  <0.001  <0.001  <0.001  <0.001  <0.001 
  1st 21.8%  20.9%  32.8%  42.9%  59.3%  
  2nd to 3rd 23.2%  22.7%  35.3%  46.4%  63.5%  
  4th to 5th 29.0%  28.4%  42.2%  53.4%  66.2%  
  6th + 35.9%  34.1%  49.5%  61.4%  66.9%  
Birth setting  <0.001  <0.001  <0.001  <0.001  <0.001 
  Institutional delivery, public 19.8%  0.2109  33.9%  45.3%  62.2%  
  Institutional delivery, private 18.9%  0.1782  29.3%  39.0%  64.2%  
  Home delivery, skilled attend. 35.7%  0.3164  45.7%  54.9%  62.2%  
  Home delivery, trad.l attend. 45.7%  0.3942  54.1%  65.2%  67.7%  
  Home delivery, no attend. 48.9%  0.3948  54.4%  64.7%  70.2%  
Fully immunized  <0.001  <0.001  <0.001  <0.001  <0.001 
  Incomplete 36.0%  40.6%  55.6%  60.9%  71.2%  
  Complete 23.5%  21.6%  38.4%  47.5%  63.0%  
Not coadministered with Polio1 -  41.1% <0.001 52.2% <0.001 58.1% <0.001 66.9% <0.001 
Not coadministered with Polio2 -  -  48.6% <0.001 53.3% <0.001 64.8% <0.001 
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Not coadministered with Polio3 -  -  -  53.3% <0.001 66.0% <0.001 
Mother's age (at childbirth)  <0.001  <0.001 1 <0.001  <0.001  <0.001 
  Under 20 28.0%  26.3%  40.3%  51.1%  61.7%  
  20-29 25.2%  24.6%  36.9%  47.9%  63.3%  
  30-39 25.6%  25.1%  38.8%  49.6%  64.7%  
  40-44 29.1%  28.4%  43.1%  54.0%  66.8%  
Mother's educational attainment  <0.001  <0.001  <0.001  <0.001  <0.001 
  None 33.3%  33.3%  48.8%  60.8%  64.1%  
  Primary 26.6%  23.9%  37.1%  48.4%  65.7%  
  Secondary 17.4%  17.8%  28.7%  38.8%  61.3%  
  Higher 10.1%  11.4%  17.9%  24.4%  57.6%  
Mother's marital status  <0.001  <0.001  <0.001  <0.001  <0.001 
  Never married 18.2%  19.6%  30.8%  38.3%  58.0%  
  Formerly married 25.1%  25.3%  39.8%  50.5%  65.6%  
  Currently married 26.6%  25.6%  38.7%  50.0%  64.0%  
Household wealth quintile  <0.001  <0.001  <0.001  <0.001  <0.001 
  Poorest 34.3%  31.9%  46.8%  58.7%  66.9%  
  Poorer 31.5%  29.2%  43.3%  54.4%  64.9%  
  Middle 27.1%  25.5%  39.2%  50.7%  63.5%  
  Richer 21.3%  21.8%  34.9%  45.8%  62.4%  
  Richest  14.1%  16.6%  25.8%  35.3%  60.2%  
Place of residence  <0.001  <0.001  <0.001  <0.001  <0.001 
  Rural 31.0%  28.0%  42.1%  53.6%  64.7%  
  Urban 16.3%  19.7%  30.9%  40.7%  61.5%   
          
Observations d 67,335  66,849  65,036  62,271  57,501  
 
a All proportions in the pooled sample account for each country’s survey design using sampling weights provided by DHS.  
b Number of children age-eligible for inclusion who had a vaccination card available at the time of interview with complete dates for administered 
doses of BCG, Penta3, Polio3 and Measles if received.  
c ‘Overall’ reflects the proportion of children vaccinated late, according to cutoffs defined in Table 1, regardless of being the first instance of delay 
or having a prior history of delayed vaccination, among children who were vaccinated. 
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d Differences in the number of observations between vaccination doses reflect dropout due to not receiving a dose or listwise deletion due to 
missing values for covariates/predictors. For BCG, 1,863 children did not receive the dose and another 808 children were excluded due to missing 
values for birth setting and/or maternal education; For Pentavalent, 1,982 (dose 1), 3,900 (dose 2) and 6,977 (dose 3) children did not receive 
doses in the vaccination series, and another 811, 796 and 758 children were excluded from the respective analytic samples due to incomplete 
vaccination dates, or missing values for birth setting or maternal education. For measles, 10,593 children did not receive the vaccine and another 
729 children were excluded due to missing values for birth setting and/or maternal education.  




Table 2.5 Association between dose-specific delayed vaccination and not completing the basic immunization schedule by 12 months of age 
in children 12-35 months across 33 countries in sub-Saharan Africa. Logistic regression a results presented as ORa and AMEb 
 BCG 
d Penta1 Penta2 Penta3 Measles BCG  d Penta1 Penta2 Penta3 Measles 





instance           























          
(ref = on-time) - 2.91*** 2.79*** 2.46*** 8.21*** 
 




















          
Observations 67,335 66,849 65,036 62,271 58,684 67,408 66,849 65,036 62,271 57,501 
 
*** p<0.001 
a For consistency across models for BCG, Penta1, Penta2, Penta3 and Measles, all models adjust for: continuous child age, birth order and setting; mother’s age 
at childbirth and educational attainment by time of interview; and household wealth quintile and location (rural/urban); survey year and country. Models for 
Penta and Measles include controls for missed opportunities of vaccination associated with recommended concomitant vaccination of Penta and Polio at 6, 10 
and 14 weeks. Not shown. 
b Odds of not completing the basic immunization schedule by 12 months of age (i.e. receiving BCG, Penta1-3, Polio1-3 and Measles1) are compared between 
children who receive delayed vaccination and children who are vaccinated on-time. The three-level delay category captures two types of delay: first instance of 
delayed receipt in the schedule and delayed at a given instance after having experienced delays at prior vaccination instances.  
c AME shows the average change in probability of the outcome when making a discrete level change in the categorical predictor defining delayed vaccination 
versus on-time vaccination, i.e. how much higher (or lower) the expected mean probability of not completing the vaccination series is in the study population 
when a child is delayed (either first instance or with prior delays) in receiving a specific vaccine dose versus receiving the dose on time, holding all other 
variables at their observed values. 




Table 2.6 Multinomial logistic regression results of factors associated with first instance/prior delays compared to on-time vaccination by 
vaccine. Results reported as adjusted Odds Ratios (aOR) and robust standard errors in parentheses 
 
BCG Penta1 Penta 2 Penta3 Measles  
Compared to on-time receipt 


















Child's sex (ref=male) 
         
Female 1.01 1.01 1.02 0.90* 1 1.01 0.96 1 0.96  
(0.02) (0.04) (0.03) (0.03) (0.03) (0.04) (0.02) (0.03) (0.02) 
Child's birth order (ref=1st) 
         
Second  1.05 1.05 1.12* 1.22*** 1.06 1.08 1.14** 1.17*** 1.29***  
(0.04) (0.06) (0.06) (0.07) (0.04) (0.06) (0.04) (0.05) (0.05) 
Third 1.20*** 1.26*** 1.34*** 1.22** 1.29*** 1.17* 1.29*** 1.25*** 1.51***  
(0.06) (0.09) (0.08) (0.08) (0.06) (0.08) (0.06) (0.07) (0.07) 
Fourth or higher order 1.39*** 1.48*** 1.62*** 1.28** 1.62*** 1.27** 1.63*** 1.12 1.64***  
(0.09) (0.14) (0.12) (0.12) (0.10) (0.12) (0.10) (0.09) (0.11) 
Birth setting (ref=Institutional, 
public) 
         
Institutional, private 1.12* 0.98 1.05 1.02 1.02 0.94 1 1.03 1  
(0.06) (0.08) (0.08) (0.07) (0.06) (0.07) (0.05) (0.05) (0.05) 
Non-institutional, skilled attendant 1.73*** 0.99 1.42*** 0.94 1.36** 0.9 1.18 0.88 1.18  
(0.15) (0.13) (0.14) (0.12) (0.14) (0.14) (0.13) (0.12) (0.12) 
Non-institutional, traditional 
attendant 
2.12*** 1.07 1.98*** 1.05 1.67*** 1.02 1.60*** 0.72*** 1.33*** 
 
(0.07) (0.05) (0.07) (0.05) (0.06) (0.05) (0.06) (0.03) (0.05) 
Non-institutional, no attendant 2.14*** 1.01 2.04*** 1.08 1.78*** 0.96 1.66*** 0.83 1.49***  
(0.15) (0.11) (0.15) (0.12) (0.10) (0.13) (0.12) (0.08) (0.11) 
Mother's age at childbirth 
(ref=15-19) 
         
20-29 0.86*** 0.97 0.83*** 0.79*** 0.88*** 0.93 0.85*** 1.01 0.88**  
(0.04) (0.06) (0.04) (0.05) (0.04) (0.06) (0.04) (0.05) (0.04) 
30-29 0.76*** 0.81** 0.72*** 0.87 0.75*** 0.88 0.76*** 1.04 0.80***  
(0.04) (0.07) (0.05) (0.06) (0.04) (0.07) (0.04) (0.07) (0.05) 
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44-44 0.76*** 0.83 0.66*** 0.86 0.71*** 0.86 0.70*** 1.1 0.82*  
(0.06) (0.10) (0.06) (0.10) (0.06) (0.10) (0.06) (0.11) (0.07) 
Mother's educational attainment 
(ref=none) 
         
Primary 0.92** 0.85*** 0.84*** 0.86** 0.82** 0.90* 0.81*** 1.13** 0.97  
(0.03) (0.04) (0.03) (0.04) (0.03) (0.05) (0.03) (0.05) (0.03) 
Secondary 0.79*** 0.68*** 0.67*** 0.65*** 0.64*** 0.78*** 0.61*** 1.27*** 0.87**  
(0.03) (0.05) (0.04) (0.04) (0.03) (0.05) (0.03) (0.06) (0.04) 
Higher 0.56*** 0.58*** 0.48*** 0.47*** 0.47*** 0.61** 0.40*** 1.24* 0.74***  
(0.07) (0.09) (0.09) (0.08) (0.05) (0.09) (0.04) (0.11) (0.07) 
Mother's marital status 
(ref=never married) 
         
Married, currently 1.00 0.95 0.99 1 0.98 1.28** 1.07 0.96 1.01  
(0.06) (0.08) (0.08) (0.08) (0.06) (0.11) (0.06) (0.06) (0.06) 
Married, formerly 1.01 1.1 1 1.13 1.09 1.23 1.19* 0.91 1.09  
(0.08) (0.12) (0.10) (0.12) (0.09) (0.13) (0.09) (0.08) (0.09) 
Household wealth quintile 
(ref=poorest) 
         
Poorer wealth quintile 0.91** 0.87** 0.88** 0.94 0.85*** 0.9 0.83*** 0.98 0.91*  
(0.03) (0.05) (0.04) (0.05) (0.03) (0.05) (0.03) (0.04) (0.03) 
Middle wealth quintile 0.80*** 0.80*** 0.78*** 0.91 0.76*** 0.91 0.76*** 1.02 0.87***  
(0.03) (0.05) (0.04) (0.05) (0.03) (0.05) (0.03) (0.05) (0.03) 
Richer wealth quintile 0.69*** 0.78*** 0.69*** 0.92 0.69*** 0.88* 0.70*** 1.04 0.84***  
(0.03) (0.05) (0.04) (0.06) (0.03) (0.05) (0.03) (0.05) (0.04) 
Richest wealth quintile 0.51*** 0.80** 0.54*** 0.74*** 0.56*** 0.74*** 0.55*** 1.16* 0.72***  
(0.03) (0.07) (0.04) (0.06) (0.03) (0.06) (0.03) (0.07) (0.04) 
Residence location (ref=urban) 
         
Rural 1.45*** 1.15** 1.33*** 1.06 1.35*** 1.05 1.32*** 0.86** 1.18***  
(0.06) (0.06) (0.07) (0.06) (0.06) (0.06) (0.05) (0.04) (0.05) 
Year of interview 0.90* 0.84* 0.88 1.08 0.89* 0.94 0.96 0.98 0.92  
(0.05) (0.06) (0.06) (0.07) (0.05) (0.06) (0.05) (0.05) (0.05) 
Child's age in months 1.01*** 1 1.01*** 1.01** 1.01*** 1 1.01*** 1 1.01***  
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) 
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Missed opportunity for 
vaccination  (ref=Polio and Penta 
co-administered) 
         
At 6 weeks - 0.36*** 0.55*** 1.27* 0.60*** 1.38** 0.74*** 1.28*** 0.97   
(0.02) (0.03) (0.12) (0.04) (0.13) (0.05) (0.10) (0.06) 
At 10 weeks - 
  
0.54*** 0.73*** 1 0.84** 1.30*** 0.91     
(0.05) (0.05) (0.10) (0.05) (0.10) (0.06) 
At 14 weeks - 
    
0.73*** 0.87** 1.25*** 0.74***       
(0.06) (0.05) (0.09) (0.04) 
Observations    67,335     66,849     65,036 62,271 58,684 
 





Figure 2-1 Percentage of children by vaccination status across the recommended series in the 
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Figure 2-2 Predicted probability of not being fully vaccinated by 12 months of age for categories of 






Figure 2-3 Country-stratified associations between dose-specific delayed vaccination (first instance delay vs. on-time administration of 





Figure 2-4 Country-stratified associations between dose-specific delayed vaccination (first instance delay vs. on-time administration of 





Figure 2-5 Country-stratified associations between dose-specific delayed vaccination (first instance delay vs. on-time administration of 
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Chapter 3 Vaccination Outcomes Among Children With a Decedent Sibling Under-Five 




Introduction: Low vaccination coverage in areas with unacceptably high rates of under-five 
death pose serious challenges for improving child health. Characterizing vaccination patterns in 
populations affected by the experience of premature under-five death may yield important 
lessons for immunization programs. This study explores the potential association between the 
community and family experience with a child under-five prematurely dying and vaccination 
outcomes in surviving children in sub-Saharan Africa (SSA).  
Methods: Using childhood vaccination records and women’s birth histories collected by 
Demographic and Health Surveys (DHS) in 33 SSA countries during 2010-2019, children 12-23 
months who had one or more siblings born in the preceding 10-years prior to the survey were 
identified. Vaccination outcomes for children were compared between those who had at least one 
decedent older sibling and those who only had surviving siblings. Associations using binomial 
models with a logit link and adjustment for clustering in the survey design at the primary 
sampling unit were estimated. Modification of family experience with under-five death by under-
five mortality (U5M) strata at sub-national levels was also explored.  
Results: 52,687 children with vaccination records who had older siblings were identified across 
33 Demographic and Health Surveys conducted between April, 2010, and January, 2019. On 
average, children evaluated for vaccination outcomes had 2.3 older siblings born within the prior 
10 years and  20% had at least one decedent sibling. Having a decedent sibling was associated 
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with significantly lower odds of children being fully vaccinated at the time of interview, 
adjusting for geo-social factors (adjusted Odds Ratio [aOR] 0.88, 95%CI: 0.78-0.97). This 
association was slightly attenuated after controlling for mother characteristics (aOR: 0.89; 
95%CI: 0.84-0.95). No effect modification due to variation in sub-national U5M was observed ( 
p for interaction = 0.44); however, residing in a higher U5M strata was independently associated 
with significantly lower vaccination schedule completion.  
Conclusion: The experiential burden of under-five death within families and higher U5M at 
province-level was associated with lower completion of vaccination schedules in surviving 
children; however, indicators of under-five mortality risk likely overlap with other barriers to 
access for immunization services in surviving children. The shared root causes of childhood 
mortality and access to immunization services merits further investigation, particularly with 
respect to lower administrative levels of analysis.  
Introduction 
As of 2019, sub-Saharan Africa accounts for nearly 50% of the 19.7 million children 
worldwide who were reported to be under-vaccinated, comprising those who have received 
some, but not all, recommended vaccines or no vaccines at all.1 For example, only 82% of 
infants born in Eastern and Southern Africa, and 76% in Central and West Africa were 
vaccinated at birth with BCG which is the first vaccine in the schedule and an important proxy 
for initiating immunization schedules.2 Given these reports, the Global Vaccine Action Plan’s 
target of achieving at least 90% coverage for all recommended childhood vaccines by the end of 
2020, which was endorsed by governments across the sub-region, appears to be out of reach for 
most African nations.3 With regional population growth estimated at 2.7% per year4, the number 
of under-vaccinated and non-vaccinated children in sub-Saharan Africa is expected to grow 
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rapidly if new approaches and renewed investment are not identified to rapidly scale-up 
vaccination. 
Increasing access to basic preventive health services such as immunization is key to 
improving childhood survival in sub-Saharan Africa5–7, where children are 15 times more likely 
to die before age-five than in high-income countries.8 In addition to sub-Saharan Africa having 
the lowest regional vaccination coverage of any other geographic regions worldwide, low 
vaccination coverage within countries in the region tends to be concentrated geographically and 
overlapping with other determinants that may predict elevated risk for premature death in 
childhood.9,10 These so-called vulnerable populations on the aggregate are considered a priority 
for immunization outreach in operational and strategic plans both globally and regionally.11,12 
Nonetheless, childhood vaccination patterns among families and communities who have endured 
the experience of losing a young child have not been well-studied. Understanding whether 
exposure to premature childhood death during motherhood motivates vaccination choices or 
shows any association with vaccination outcomes for surviving children may be helpful for 
developing evidence-driven outreach and education to the populations deemed as a priority for 
strategic immunization activities. 
Social and individual bereavement experiences and learning following the death of a 
young child is one of the most studied phenomena of countries undergoing demographic 
transitions, commonly cited as a driving determinant of subsequent health and fertility decisions 
at the individual level.13 Applying this theoretical framing to high U5M settings early in their 
demographic transitions such as that of sub-Saharan Africa14, bereaved parents, and community 
members, via learning from their social networks, might seek to improve survivorship of live 
births through increased utilization of health promotion activities15 like immunization. However, 
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this contradicts the observed reality of low vaccination coverage persistently being a problem in 
geographic areas with an elevated risk of childhood mortality.16 Another explanation for this 
pattern could be that the experience of losing a child prematurely is an indicator of other barriers 
to access. The direction of this relationship and whether it exists at all is best explored at an 
individual level, comparing vaccination outcomes among surviving children between families 
and communities who have differing levels of experience with under-five death. 
Since 1984, the Demographic and Health Survey (DHS) has collected complete birth 
histories and childhood vaccination records from mothers sampled in participating countries.17 
As a highly utilized and standardized survey, the DHS has been one of the most important 
sources of data for evaluating predictors of immunization internationally.17 This study uses 
recent DHS data from 33 sub-Saharan African countries to examine the relationship between the 
occurrence of under-five death among children born in the preceding 10-year period and 
vaccination outcomes in surviving children. 
Methods 
Data sources, study population and timeframe 
DHS data was obtained from all SSA countries where a DHS survey was conducted 
between 2010-2019 (available as of 06/2020) (Table 3.1). Using a standardized household survey 
design approach across participating countries, the DHS partners with local institutions to collect 
nationally representative health and demographic data to inform health policy and program 
decision-making at national and global levels.18 The sample design and survey methodology for 
this widely used data source has been thoroughly described elsewhere.17 Briefly, the DHS 
employs a two-stage sampling procedure where sub-national geographic areas are chosen for 
inclusion using a probability of selection proportional to the area’s population size and other 
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stratification characteristics. In the second stage, field workers generate a complete listing of 
households in the sampled areas and then systematically select 20-30 in each area for 
interviews.19 
All women aged 15-49 from households selected for the survey are interviewed using an 
extensive questionnaire, which asks women about their health behaviors, contraceptive and 
reproductive preferences, health service utilization, and the survivorship and health of any 
children. Women also provide a complete birth history for up to 20 births. 20 For each live birth 
in the 3-5 years prior to the interview (with the time interval dependent on the country-specific 
adaption of the protocol), women report their children’s vaccination status, including the number 
of vaccine doses and dates of administration for each up until the date of interview.20,21  
Exposure to premature childhood death in a family over a 10-year period was defined by 
evaluating the women’s complete birth histories. From the immunization records collected, 
vaccination outcomes were determined for surviving siblings who were 12-23 months at the time 
of the interview (index children). All index children who had no siblings, only younger siblings 
or siblings who were born more than 10 years prior to the interview were excluded. After linking 
sibling history to vaccination outcomes of index children, descriptive variables defining the order 
of relationship between the index child used for vaccination outcomes and any siblings were 
derived to sibships that met exclusion criteria. Finally, all but the oldest index child from 
multiple births or close interval births were excluded to avoid correlated outcomes among the 
small proportion of families who had more than one child aged 12-23 months at the time of 
interview. 
To the authors’ knowledge, no studies have used the DHS birth histories to construct a 
period-exposure of under-five death within a family on surviving siblings’ vaccination outcomes. 
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Although one study15 evaluating the association between preceding sibling death and maternal 
and child health services utilization was identified in the literature, there was no clear 
explanation provided for the decision to study only the preceding child’s survival exposure. As 
an exploratory approach, the exposure period for this study was defined as the 10 years prior to 
interview, considering the potential influence of maternal recall bias beyond this time period.  
Outcome 
The primary outcome of interest was a dichotomized indication of receipt of all basic 
recommended vaccines by the time of interview, often referred to as up-to-date or fully 
immunized. For the present study, index children were considered fully immunized (FIC [fully 
immunized child]) if their vaccination record data indicated that they had received one dose of 
Bacillus-Calmette-Guerin (BCG), three doses of Oral polio vaccine (Polio) and 3 doses of the 
Pentavalent (Penta) combination vaccine (i.e. diptheria-tetanus-pertusis [DPT] – Hepatitis B 
[HepB] – Haemophilus influenzae type b [Hib]) and one dose of Measles-containing vaccine 
(MCV) prior to the interview occurring in the 12-23 month of age window The use of IPV in 
addition to OPV in low- and middle-income countries is a recommendation only from 2013, 
which falls in the middle of the decade selected for survey inclusion, and therefore this vaccine 
was not evaluated.22 
Exposure to sibling death  
Older sibling deaths in the prior 10-year period that occurred before 59 months of age i.e. 
age at death, were flagged. We chose to limit our study of the experience of child death on 
vaccination outcomes to death in the childhood period considering that any subsequent parental 
behavior changes to childhood vaccination would implicitly target survivorship under-five. Index 
children were assigned to the exposure category if at least one older sibling had died before the 
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age of five, and otherwise assigned as not exposed. Although the cumulative number of older 
sibling deaths per index child was tallied, any death experience in the exposure period was used 
as the initial exploratory exposure and the cumulative number of decedent older siblings was 
explored in sensitivity analysis.  
Covariates 
While it was not an aim to determine causal pathways in this exploratory analysis, there 
are several factors that may bias the association between childhood sibling death exposure and 
vaccination outcomes for the surviving sibling, some of which were unavailable in the DHS, 
described in the directed acyclic diagram available in Figure 3-1. Sociodemographic and 
economic factors at community or household-levels that were available in the DHS or using the 
authors’ own construction were evaluated, such as household wealth, rural versus urban 
residence location, and 10-year under-five mortality (U5M) for the region of residence within 
each child’s respective country. Household wealth quintiles were provided by DHS based on a 
household asset module and index construction via Principle Component Analysis (PCA). Rural 
versus urban geographic residence location was determined at the country-level. U5M at the 
level of each country’s region/province was calculated over the exposure period of 10 years prior 
to the interview. Following DHS guidance21, component probabilities of survival were estimated 
and then the conditional probability of survival by age five per 1000 live births was generated 
using DHS.rates package in R.23 Finally, community-level exposure to underlying rates of 
childhood mortality was operationalized by converting the continuous U5M per 1,000 live births 
to quartile cut-offs in the distribution, creating a 4-level categorical variable: low (<64.5 per 
1000 live births), low-medium (64.5-88 per 1000 live births), medium-high (89-125 per 1000 
live births), and high (>125 per 1000 live births).  
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Mother-level covariates included educational attainment and maternal age at the woman’s 
first birth. Educational attainment was categorized as none, primary, secondary or higher levels. 
The continuous measure of age at first delivery was converted to a categorical variable, grouping 
<15 years, 20-24 years, 25-29 years, and 30-44 years of age. Finally, the total number of children 
born in the 10 year exposure period was also considered. 
Statistical analyses 
The sample was described by stratifying covariates on the exposure to assess potential 
levels of confounding, which informed a purposeful approach to variable selection for inclusion 
in statistical models. Bivariate associations between all independent variables and the outcome 
were assessed. All variables showing a statistically significant association with the outcome at 
the level of <0.20 were considered for inclusion. Using a between mother analytical approach 
after restricting the sample to one index child per mother, the association between the sibling 
death exposure and vaccination outcome in the index child was estimated using binomial models 
with a logit link. Sequential and purposeful forward selection was used to adjust for observed 
confounding. Model 1 adjusted for household and higher-level variables; Model 2 adjusted for 
mother-level covariates; and Model 3 adjusted for child-level covariates. Joint F-tests and 
significance level for each set of covariate betas were considered to determine the overall 
suitability of the model to inform interpretation.24  
Additionally, assessing the heterogeneity in the main effect across community-level 
experience with under-five death was explored to ascertain whether associations between under-
five death in a family and vaccination outcomes in subsequent children varied across levels of 
U5M in the community, testing the hypothesis that the association of under-five death in a family 
and subsequent vaccination outcomes may be conditioned on the community level experience 
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with U5M. Lacking this type of information specifically in the DHS, we used the categorical 
derivation of U5M at the regional/province-level as a proxy for community exposure and 
interacted this variable with the primary exposure at the family-level. We reported adjusted Wald 
tests for interaction terms, and only maintain terms significant at the 0.05 alpha level. 
All models controlled for unobserved confounding between countries using a dummy 
indicator term and using continuous variable for year of interview. Survey procedures were used 
to account for the stratified cluster sample design within each country, using the women’s 
weights provided by DHS and re-weighting them to give equal weight to each country-year 
survey. All analyses were conducted in 08/2020 using Stata version 16 (Statacorp, LLC; College 
Station, TX). 
Results 
A total of 69,552 sampled children 12-23 months were assessed for vaccination status 
across 33 sub-Saharan African countries by DHS between 2010-2019. 16,922 children were 
excluded from this study after not meeting inclusion criteria (Figure 3-2). Among 52,687 
children retained for the sample, the average age was 17.22 months, there were equal numbers of 
female and male children, and nearly 45% were only the 2nd or 3rd birth in the family (Table 3.2)  
Mothers of the children were predominantly young (56% aged 15-19; and 30% aged 20-24) at 
the time of their first birth, and lacked any education (44% reporting no formal education). The 
sample was characterized by more than two-thirds residing in rural areas, and nearly a quarter 
belonging to the poorest wealth quintiles (Table 3.2). 
On average, children had 2.27 siblings who had preceded them in the prior 10-years in 
the family birth order, which was higher for families who had experienced an under-five death in 
the prior 10 years (mean 3.02, standard error 0.01). A total of 10,559 (20%) of children in the 
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sample were born to families who had experienced the premature death of at least one preceding 
child. A larger proportion of children born to families who had experienced a prior child death in 
the under-five period were 4th or higher birth order than children who had no prior sibling deaths. 
These children lived in rural areas in larger proportions (77% vs 67%), had mothers with greater 
levels of little to no formal education (85% vs 74%), and younger mothers at their first childbirth 
(<20: 67% vs 60%). Children born to families with prior young sibling death also were fully 
immunized at a lower proportion (51% vs 58%). Table 3-2 further describes the sample stratified 
on the main effect. 
The models used to estimate the association between exposure to under-five death in a 
family (using the experience of death in siblings preceding the observed childhood vaccination 
outcomes) and subsequent surviving children being fully immunized provided varying absolute 
estimates of the relationship, but all associations suggested that experience with under-five death 
within families reduced the likelihood of surviving children being fully immunized. Model 1 
(without any adjustment) estimated that the odds of being fully immunized (FIC) in children 
born to families who had experienced an under-five death in the previous 10-year period was .75 
times the odds of being FIC for children without a prior sibling death (95%CI: 0.71-0.79). 
Adjusting for factors at the household and community-levels, and then adding mother-level 
covariates , the association was slightly attenuated and approaching the null, respectively, 
(Model 2 - aOR:0.88; 95%CI:0.78-0.97) and (Model 3 – aOR: 0.89; 95%CI:0.84-0.95). The final 
model adjusted for the number of older siblings, which showed a non-significant association, just 




 The likelihood of children being fully vaccinated in their early childhood among families 
who had experienced the premature death of a prior child did not significantly differ across strata 
of under-five mortality, after considering the potential for heterogeneity in the association by 
including an interaction term (p for interaction = 0.44; not shown). The variation in probability 
of being fully vaccinated associated with a prior sibling death across mortality strata was 
assessed qualitatively by plotting the average marginal effects and 95% confidence intervals (not 
shown). As was observed in testing the statistical significance of the interaction term, the 
confidence intervals were wide, overlapping between strata, and, except for the low-medium 
mortality strata, crossed the null. However, pooled U5M strata at the provincial level over the 
10-year period prior to the survey was independently associated with vaccination outcomes in 
children sampled, revealing that children who resided in higher mortality strata areas were less 
likely to be fully vaccinated in early childhood (Model 3: low-medium vs low – aOR:0.89, 
95%CI 0.81-0.97; medium-high vs. low – aOR:0.89, 95%CI 0.81-0.98; high vs low – aOR:0.80, 
95%CI 0.71-0.90). In sensitivity analysis, the cumulative number of decedent siblings was tested 
for potentially being a more appropriate measure of U5M experience in a family, but the findings 
did not differ from the main analyses. 
Discussion  
Persistently high childhood mortality in the presence of low vaccination uptake within 
many communities in sub-Saharan Africa is a considerable obstacle for sustained improvement 
of childhood survival. At the end of 2015, the year which marked the conclusion of the 
Millennium Development Goals and an unprecedented global effort to improve childhood 
survival, nearly 25% of childhood deaths in sub-Saharan Africa were still due to causes 
potentially preventable by vaccination.25 Characterizing vaccination patterns in families and 
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communities most afflicted by high U5M is urgently needed to understand how to adapt 
education and outreach in the years ahead as countries work towards reducing childhood 
mortality to fewer than 25 under-five deaths per 1,000 live births, in accordance with the updated 
global health goals stated in the 2030 Sustainable Development Goal (SDG) Agenda. In this 
regard, the impact of child mortality within a family and community on parents’ subsequent 
preventive health service seeking behavior for their surviving children is an under-studied 
pathway for targeting interventions that may help improve vaccination among the most 
vulnerable populations.  
To the authors’ knowledge, this study is the first to compare vaccination outcomes among 
families who have experienced the premature loss of a child to families with no prior history of 
childhood death. We found that after adjusting for factors that are known to influence 
vaccination behavior and access, the likelihood of children being fully vaccinated following a 
premature death among older siblings in the family did not differ significantly from children with 
no prior sibling deaths; however, the confidence interval for the association only barely crossed 
the null after controlling for the number of siblings and otherwise the estimated associations 
showed that the experience of childhood death was associated with poor vaccination outcomes in 
surviving children. We also found that families residing in areas with a higher probability of 
under-five death were significantly less likely to have their children fully vaccinated compared to 
families living in the lowest U5M burden areas.  
This study was initially motivated by a supposition that parents, caretakers, or community 
leaders may change their risk-benefit calculation of health decisions following direct experience 
with a child dying in early life due to a desire to make assurances about their surviving children’s 
continued survivorship. However, this hypothesis assumes families and communities have no 
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other barriers to accessing immunization services following a shift in risk perception or 
motivation that changes care-seeking behaviors that we know does not hold. It also presupposes 
that the experience of childhood death in a family would motivate differential vaccination uptake 
in surviving children. Residing in higher U5M strata at the sub-national level was predictive of 
worse vaccination outcome, which suggests that clustering of under-five death shares a bi-
directional relationship with access disadvantages.  
This complicates any program’s outreach targeting strategies when children who are at-
risk share socioeconomic, geographic, or other access disadvantage that are predictive of barriers 
to immunization, which further contributes to concentrating the risk of under-or non-vaccination. 
Sibling death as a determinant of maternal health service utilization in subsequent pregnancies 
was explored in a Nigerian study, where no association was found after similarly controlling for 
other predictive factors of access.15 Although the authors used a similar approach to ours, 
decisions that women make about their own health may be affected differently from child death 
than decisions they make on behalf of their surviving children. In Kenya, researchers assessed 
predictors for infant influenza vaccination as an important preventive health service, including 
history of hospital admission or death of a sibling under-five in the year preceding the 
vaccination campaign.26 In contrast to our evidencing of a direction of relationship, though non-
significant, that suggests experience of child death is a barrier to favorable vaccination outcomes 
in surviving siblings, Otieno et al. 2014 found that children of families with a history of sibship 
hospitalization (AOR: 1.73; 95%CI 1.40-2.14) or death (AOR:1.48; 95%CI0.74-2.96) were more 
likely to receive influenza vaccine during the campaign than their comparator, findings that are 
line with our initial hypothesis. One explanation for the difference in their findings from those 
observed in our study could be that Otieno et al. 2014 assessed respiratory associated hospital 
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admission and death exposure as opposed to any cause. Had information on the cause of under-
five death been available to us, we might have observed a stronger positive response in 
vaccination outcomes following a death in the family associated with vaccine-preventable 
causes. 
Several countries in the sub-region have established health and demographic surveillance 
systems to track vital statistics and other health indicators in vulnerable populations.27 Using 
platforms such as INDEPTH that allow for prospective follow-up, the study of associations 
between sibling death or community concentration of under-five mortality and near-term health 
behaviors could help clarify the utility of tracking infant and child deaths in a family as a risk 
factor for uptake of vaccination. Other cohort studies in high-income settings, such as 
Scandinavia, have found a 1.7 to 2-fold increase in instantaneous mortality risk for individuals 
who experience the death of a sibling in early childhood.28 However, the mechanisms for the 
increased risk of death following exposure to a sibling death were not studied. Future studies 
might also consider collecting data on changes in parental perceptions of vaccination and other 
health service utilization to allow for more precise study of the parent/caretaker effect on health 
seeking behavior on behalf of their surviving children following the death of preceding children. 
There has been recent attention to the consideration of the concentrated effect of childhood 
mortality on health and wellbeing outcomes in Africa, by assessing under-five mortality from the 
perspective of the bereaved mother or community instead of spreading the experience across 
families and communities who have not experienced child death with the typical probability of 
survival measures.29 A recent methodological paper published an approach to considering the 
cumulative bereavement exposure during a mother’s lifetime by estimating the maternal 
cumulative prevalence of under-five mortality.30 These measures may more precisely capture the 
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community exposure bereavement that was intended with the use of sub-national U5M in this 
paper. To further understand the determinants of vaccination among families and communities 
who have experienced death of their children, we might consider how the magnitude of 
association changes across socioeconomic strata in place of confounder adjustment. This might 
help strengthen the hypothesis that U5M represents an indicator for disadvantage to accessing 
health services. Similarly, we could also consider evaluating how premature death of a child 
within a shorter time interval prior to the vaccination status assessment of surviving children 
changes compared to the interval of 10 years used in this study. If the direction and magnitude of 
the association are unchanged with the shorter exposure interval, we would assume that 
childhood death, even following an acute bereavement period, indicates disadvantage to 
accessing immunization services. This latter approach also would more appropriately control for 
temporal changes to socioeconomic status that are not observed between a prior childhood death 
and the wealth status captured at the time of interview. 
There are several limitations to this study. Proxy measures for community and family risk of 
under-five death were identified in the data available, which may not be suitable units of analysis 
for children who do not live in the same household as their preceding siblings who died or where 
administrative provinces represent artificial divisions of risk. In this sense, misclassification of 
exposure assignment to sibling/community under-five death could have biased the associations. 
Considering spatial coordinate data in future analyses would be helpful. Secondly, the cause of 
death for children in the DHS is unknown. While causes of death associated with illness that can 
be preventable with vaccines is still very common in SSA (e.g., diarrhea, bacterial pneumonia 
and sepsis, measles), the distribution of death causes for siblings identified in this study could 
skew differently. In this sense, the associations may have been more obvious if analysis were 
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restricted to only deaths associated with infectious causes especially those which were vaccine-
preventable. Finally, owing to the cross-sectional data source, time-varying confounders were 
not available. However, the temporal ordering of a sibling death prior to observing vaccination 
outcomes in subsequent children was achieved with the use of complete birth histories collected 
by the DHS.  
Conclusion 
The experiential burden of under-five death within families and higher U5M at province-
level was associated with lower completion of vaccination schedules in surviving children. 
However, indicators of under-five mortality risk likely overlap with other barriers to access for 
immunization services in surviving children. The shared underlying determinants of childhood 
mortality and access to immunization services merits further investigation, which may be more 
feasible to study ecologically using geospatial data at lower administrative levels or considering 





















Angola 2015-16 2,845 2,183 77% 4.1% 28.6% 68 
Burkina Faso 2010 2,790 2,238 80% 4.2% 81.3% 129 
Benin 2017-18 2,522 1,912 76% 3.6% 55.7% 96 
Burundi 2016-17 2,596 2,086 80% 4.0% 84.9% 78 
Congo Dem. 
Republic 2013-14 3,438 2,709 79% 5.1% 44.3% 104 
Congo 2011-12 1,883 1,397 74% 2.7% 39.1% 68 
Cote D'Ivoire 2011-12 1,416 1,050 74% 2.0% 50.2% 108 
Cameroon 2011 2,278 1,682 74% 3.2% 50.5% 122 
Ethiopia 2016 1,929 1,471 76% 2.8% 36.8% 67 
Gabon 2012 1,187 853 72% 1.6% 6.4% 65 
Ghana 2014 1,128 837 74% 1.6% 79.7% 60 
Gambia 2013 1,645 1,245 76% 2.4% 78.4% 54 
Guinea 2018 1,408 1,095 78% 2.1% 22.4% 111 
Kenya 2014 4,048 3,003 74% 5.7% 70.3% 52 
Comoros  2012 626 464 74% 0.9% 62.0% 50 
Liberia 2013 1,432 1,078 75% 2.0% 50.6% 94 
Lesotho 2014 655 360 55% 0.7% 66.3% 85 
Mali 2018 1,946 1,559 80% 3.0% 43.9% 101 
Malawi 2015-16 3,248 2,333 72% 4.4% 75.1% 64 
Mozambique 2011 2,225 1,655 74% 3.1% 62.8% 97 
Nigeria 2018 6,059 4,796 79% 9.1% 29.7% 132 
Niger 2012 2,147 1,808 84% 3.4% 50.8% 127 
Namibia 2013 991 636 64% 1.2% 71.6% 54 
Rwanda 2014-15 1,536 1,073 70% 2.0% 41.5% 50 
Sierra Leon 2013 2,083 1,561 75% 3.0% 67.5% 156 
Senegal 2017 2,390 1,774 74% 3.4% 74.5% 56 
Chad 2014-15 2,870 2,454 86% 4.7% 24.9% 133 
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Togo 2013-14 1,404 1,019 73% 1.9% 59.3% 88 
Tanzania 2015-16 2,158 1,571 73% 3.0% 73.0% 67 
Uganda 2016 2,922 2,189 75% 4.2% 55.5% 64 
South Africa 2016 670 380 57% 0.7% 60.9% 42 
Zambia 2018-19 1,926 1,422 74% 2.7% 74.4% 61 
Zimbabwe 2015 1,151 794 69% 1.5% 74.9% 69 
 
a: Total number of children 12-23 months at time of interview in each nationally representative sample; b: Total number of child 
observations in country survey samples identified as (1) having vaccination records by review of vaccine cards or maternal recall, and 
(2) having a preceding sibling born within 10-years of the survey date; c: Proportion of children who meet study inclusion criteria that 
are fully immunized, defined as having record of all 8 basic vaccinations by the time of interview (maternal recall or vaccine card 
review) in the DHS, adjusted for survey design; d: U5M = Under-five mortality at national-level during the 10-year period prior to 
survey interviews, calculated using DHS birth histories and adjusted for survey design. 
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Table 3.2 Distribution of characteristics of children 12-23 months sampled in included DHS 
surveys, sub-Saharan Africa, 2010-2019. Unweighted frequencies and weighted proportions/means 





 sibling death 
 
No prior  
sibling death 
 n=52,687  n=10,559  n=42,128 
 
 
Unweighted frequencies (weighted %) or *Weighted Mean (SE) 
      
Index child's 
age, months*  17.22 (0.02)  17.24 (0.05)  17.22 (0.02) 
Sex      
Male 26,536 (50.0%)  5,319 (49.3%)  21,217 (50.4%) 
Female 26,239 (50.0%)  5,345 (50.7%)  20,894 (50.6%) 
      
# older 
siblings born 
in prior 10 
years* 2.27 (0.01)  3.02 (0.02)  2.09 (0.01) 
Birth order 
rank      
2nd-3rd 23,513 (45.9%)  2,717 (26.9%)  20,796 (50.6%) 
4th-6th 20,413 (38.1%)  5,019 (45.7%)  15,394 (35.9%) 
7th + 8,761 (16.0%)  2,823 (26.4%)  5,938 (13.4%) 
Maternal age 
at first birth      
<15 3,528 (6.6%)  957 (9.3%)  2,571 (5.9%) 
15-19 29,584 (55.6%)  6,254 (58.2%)  23,330 (54.9%) 
20-24 15,677(30.2%)  2,806(27.5%)  12,871 (30.9%) 
25-29 3,247 (6.4%)  452 (4.3%)  2,795 (6.9%) 
30-45 651 (1.3%)  90 (1.0%)  561 (1.4%) 
Maternal 
education      
None 23,140 (43.7%)  5,606(53.9%)  17,534 (41.2%) 
Primary 18,178 (32.9%)  3,438 (31.1%)  14,749 (33.4%) 
Secondary 10,164 (21.0%)  1,417(14.1%)  8,747 (22.8%) 
Higher 1,200 (1.3%)  97 (1.0%)  1,103 (2.7%) 
Residence 
type      
Rural 37,851 (69.1%)  8,361 (77.4%)  29,490 (67.0%) 
Urban  14,924 (30.9%)  2,303 (22.6%)  12,621 (33.0%) 
Household wealth     
Poorest 14,208 (24.0%)  3,283 (28.9%)  10,925 (22.7%) 
Poorer 11,877 (22.3%)  2,616 (24.9%)  9,261 (21.8%) 
Middle 10,494 (20.3%)  2,101 (20.2%)  8,393 (20.4%) 
Richer 8,956 (18.7%)  1,597 (16.3%)  7,359 (19.3%) 
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Richest 7,152 (14.7%)  962 (9.9%)  6,190 (15.9%) 
Under-five mortality, 
regional residence     
Low  13,143 (25.6%)  1,569 (14.9%)  11,574 (28.3%) 
Medium-
low 13,107 (24.4%)  1,981 (18.2%)  11,126 (25.9%) 
Medium-
high 13,118 (25.5%)  2,779 (27.3%)  10,339 (25.0%) 
High 13,319 (24.5%)  4,230 (39.6%)  9,089 (20.1%) 
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Table 3.3 Logistic regression results for assessing the association between under-five death in preceding children over a 10-year period 
and vaccination outcomes in surviving siblings. Pooled analysis in 33 DHS countries, 2010-2019 
 
Model 1  
(unadjusted) 
Model 2  
(adjusted, geo-
social) 
Model 2  
(adjusted, geo-social + 
mother) 
Model 3 
(adjusted, geo-social + 
mother + child) 
 Odds Ratios (ORs) comparing odds of fully immunized status in  
children with and without prior sibling death, (95% Confidence Intervals) 
Sibling death in prior 10 
years     










Residence location     








Under-five mortality,  
regional level     
Low (1st quartile)  Ref Ref Ref 
Low-Medium (2nd quartile)  
0.88 ** 
(0.80-0.96)** 








(0.81 - 0.99) 
0.89 *  
(0.81-0.98) 







Household wealth      
Poorer  Ref Ref  






























Maternal education     
None   ref Ref 
Primary   




Secondary   
1.61 *** 
(1.46-1.77) 
1.60 ***  
(1.45-1.76) 




(1.32 - 2.18) 
Maternal age (at first child 
birth)     
<15 years    Ref 
15-19 years   













(1.11 - 1.50) 
 30-45 years   
1.29 * 
(1.01 - 1.64) 
1.32 * 
(1.03-1.68) 
Older siblings born, 
continuous    
0.89 *** 
(0.86-0.93) 
Year, continuous yes yes yes yes 
Country, indicator 
categorical yes yes yes yes 









This DAG represent the hypothesized relationships between the main predictor variable (in green) and the outcome (in dark blue), 
while considering other observed confounders (in red), representing unobserved confounders (in white) anexposure variables that may 
Occurrence of <5 death among 
preceding siblings within prior 
10 years 
Fully immunized child in 
surviving younger sibship 
Index child rank 
Mother’s education Household wealth 
Maternal age, at first 
birth 
Vaccination outcomes in 
older siblings 
Rural residence 
Cause of older 
sibling <5 death 
 




Index child birth setting 
Figure 3-1 Direct Acyclic Diagram for evaluating the relationship between under-five childhood death and vaccination 
outcomes in surviving siblings within families 
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play a mediated role in the overall effect (in light blue). Thevariables in light blue were excluded from the analysis. Variables in white 





Figure 3-2 Flow diagram of sample selection for assessing the relationship between under-five 
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Chapter 4 New Vaccine Introduction and Childhood Vaccination Timeliness in Two Urban 
Informal Settlements in Nairobi, Kenya 
 
Abstract 
Introduction: New vaccine introduction accompanied by social mobilization activities could 
contribute to improved routine immunization timeliness. This study assesses the impact of 
Kenya’s introduction of PCV on the timeliness of routine childhood vaccination in two informal 
urban  settlements in Nairobi. 
Methods: Data collected from 2003-2015 as part of a demographic surveillance system was used 
to estimate annual vaccination delays among children 12-23 months of age in the period before 
and after the introduction of PCV in the Kenyan Expanded Programme on Immunization. 
Binomial segmented regression models using generalized estimating equations examined the 
association between vaccine introduction and timeliness of routine immunization. 
Results:  Over 50% of children in the two urban areas were vaccinated with 1 or more doses 
after the recommended age period from 2007-2015. The timeliness of routine immunization 
showed slight improvements or non-significant changes during the years following PCV 
introduction compared to the preceding years  (adjusted Prevalence Ratio [aPR]: 0.67, 95% 
Confidence Interval [95%CI]: 0.45-0.99 for BCG  receipt; aPR: 0.59, 95%CI: 0.41-0.83 for 
DPT3 receipt; aPR: 1.19, 95%CI: 0.99-1.42 for Measles). Delayed vaccination was still 
prevalent in 2015, particularly among the poorest residing in the settlements. 
Conclusions: Many sub-Saharan African countries have introduced new vaccines into their 




mortality. Additional evidence regarding the positive or neutral influence of new vaccine 
introduction on the performance of delivery systems provides further justification to sustain the 
inclusion of these more costly vaccines in the immunization schedule. 
 
Introduction 
Over the past two decades, the development and broad adoption of new childhood 
vaccines has resulted in remarkable improvements in child health. 1  However, at the time of 
their introduction into the global market, new vaccines were prohibitively expensive for low-
and-middle income countries (LMIC), resulting in substantial lags in their adoption compared to 
in wealthier countries .2 Additionally, new vaccine introduction implies other financial burdens 
on ministries of health such as upgrading outdated or strained immunization program 
infrastructure, improving surveillance systems, and investing in training and planning for safe 
and effective delivery strategies .3 Despite these considerable financial and logistical obstacles, 
the lag in implementing new vaccine offerings has diminished in recent years for many parts of 
sub-Saharan Africa (SSA).4 
The principle priority of contemporary immunization programs is achieving and 
maintaining high-levels of uptake for all childhood vaccines, many of which are critical to 
disease control and elimination efforts.5 Effective protection against these diseases requires 
uniformly high levels of coverage in target populations at recommended age intervals, achieving 
‘on-time’ vaccination.6 That is, vaccines delivered too early may not confer adequate levels of 
long-lasting protection and vaccines delivered too late may result in unnecessarily prolonged 
periods for which children are at-risk of more serious illness or death from vaccine-preventable 




have become more complex and vaccination programs potentially more strained, which may 
negatively influence the performance of routine immunization services. Nonetheless, social 
mobilization, outreach, and information campaigns that often accompany the launch of new 
vaccines may positively influence routine immunization services, specifically creating synergies 
between the newly introduced vaccines and others already in the schedule around the overall 
timeliness of vaccination receipt.  
Among the most rapidly developing economies in SSA, Kenya has made immunizations 
a health priority, introducing new vaccines ahead of many other LMICs, such as pneumococcal 
conjugate vaccine (PCV), in 2011, and rotavirus vaccine (RV), in 2014.9 The Kenyan Expanded 
Programme on Immunization (KEPI) was established in 1980 by the Ministry of Health to 
provide vaccinations and monitor vaccine-preventable childhood illness and death. As of 2020, 
the routine childhood immunization schedule provided by KEPI includes one dose each  of 
Bacille Calmette-Guerin (BCG) and Oral Polio Vaccine (OPV) at birth; three doses each of 
Diptheria – Tetanus – wPertussis - Haemophilus Influenzae Type B [Hib] - Hepatitis B [HepB] 
(Pentavalent), OPV and PCV at 6, 10 and 14 week; two doses of RV at 6 and 10 weeks; one dose 
of Inactivated Polio Vaccine (IPV) at 14 weeks; and two doses of Measles and rubella (MR) at 9 
and 18 months of age.  
 Though specific to only a few settings, qualitative research on the health systems impact 
of new vaccine introduction has suggested existing challenges to chronically underfunded health 
systems and programs may be exacerbated, such as overextending the limited number of 
healthcare workers with new vaccine promotion activities and as a result unintentionally 
detracting from other high priority disease elimination goals.3,10 By contrast, other research has 




strengthen healthcare workforce capacity and to further promote the benefit of immunization 
services as a whole, leveraging the availability of additional government resources or donor 
funding11–13. To date, few studies have quantitatively assessed the influence of new vaccine 
introduction on immunization program outcomes. Of those published14–18, none are specific to 
Kenya’s experience with recent new vaccine introduction in urban poor contexts. In this study, 
we describe and explore the potential impact of new vaccine introduction, using the experience 
of PCV as an example, on the timing of other vaccines recommended for routine use in two 
vulnerable, urban poor communities in Nairobi, Kenya. Using data from the Nairobi Urban 
Health and Demographic Surveillance System, we cross-sectionally assess annual trends in 
vaccination delays for routine immunization doses recommended at birth (BCG), 6, 10, 14 weeks 
(Pentavalent [Penta] and OPV) and 9 months (Measles) of age among children residing in the 
surveillance areas located in Viwandani and Korogocho, urban informal settlement communities 
within Nairobi, before and after the introduction of PCV.  
Methods 
Study setting: The Nairobi Urban Health and Demographic Surveillance System 
The Nairobi Urban Health and Demographic Surveillance System (NUHDSS) was 
established to study the health effects of migration and poverty in the urban capital of Kenya. 
Managed by the African Population and Health Research Center (APHRC), the NUHDSS 
monitors health and demographic trends through the registration of all births, migratory 
movements, and deaths in two informal settlement communities, Korogocho and Viwandani, that 
were selected as examples of the diverse experience of slum-dwelling in Nairobi.19  Circular 
migratory patterns between rural Kenya and Nairobi are common in both settings, though 




are generally characterized by spousal co-residence and multi-generations of families that 
relocated from rural areas of Kenya beginning in the 1960s. In contrast, Viwandani’s proximity 
to neighboring industrial areas attracts younger household heads, often settling temporarily 
without their entire family units, and fewer than 5% of residents are born in the settlement.20,21 
Violence coupled with absent security measures, poor or lacking infrastructure for sanitation, and 
governance issues related to land ownership disputes pose serious challenges to improving the 
health and wellbeing of the populations residing in both communities.19,22 APRHC and partner 
agencies have used data from the NUHDSS to inform policy and programmatic changes that aim 
to improve the living conditions and health situation in Viwandani, Korogocho and other slums 
of Nairobi.23  
All household units occupying dwellings in Korogocho and Viwandani were recruited for 
participation beginning in 2002. Since then, community interview teams staffed and trained by 
APHRC have visited the surveillance catchment every 120 days to update the surveillance 
system’s register of participating residents, removing individuals who have out-migrated or died 
and incorporating births and individuals who have in-migrated. At recruitment, demographic and 
migration pattern data are collected for each member of the household and then information is 
collected on in- and out-migration, births, deaths, maternal and child health, and economic and 
food security  during subsequent field interview visits.19,21 As of 2018, the NUHDSS monitors 
88,974 individuals who reside in 33,462 households in Viwandani and Korogocho and every 
year approximately 1,500 to 1,900 new live births are registered in the surveillance system.24  
Study population sample: Children 12-23 months followed in the NUHDSS 
As part of the maternal and child health focus of the system, the NUHDSS collects a 




Mothers or caretakers to age-eligible children provide a complete history of vaccination, and 
interviewers review card documentation to verify the date and number of doses for each vaccine 
received. Vaccination status is updated in the surveillance system for each child at every 
subsequent visit until the schedule is completed or the child is no longer age-eligible. Data on 
children aged 12-23 months at the time of interview was used for all publicly accessible years of 
surveillance data: 2003-2015.  To reduce selection bias that may result from loss to follow up or 
survivorship during the 12-23 month period, the first vaccination record created in the system 
following 12 months of age was included for analysis. Vaccination records were matched to 
demographic data for each child and their households collected for the same year. Children who 
never had a vaccination card reviewed or who did not have a card available in the 12-23 month 
period were excluded from analysis.  
Variables 
The primary outcome was a binary variable of delayed versus on-time vaccination 
relative to the age-specific recommendations for vaccination at birth, 6 weeks, 10 weeks, 14 
weeks and 9 months of age in Kenya for all vaccines recommended prior to the introduction of 
new vaccines (Table 4.1). Vaccination records that reported age at vaccination before the child’s 
birthdate or other implausible vaccination dates, e.g. measles vaccination at birth, were excluded 
from analysis. Delays were defined as any vaccine dose that was administered four or more 
weeks after the recommended age of vaccination (Table 4.1). All vaccines administered within 
the time interval between the recommended age and the four-week delay window were 
considered acceptable timing for receipt and defined as on-time. Vaccination series completion, 
defined as receipt of all recommended vaccines by the age of 12 months, and dose-specific 




ethnicity, and household wealth status were directly obtained from residency records. There was 
incomplete information in the system to identify all mother-child pairs, and therefore mother 
characteristics were not examined in this analysis. 
Analysis 
The distribution of demographic characteristics and vaccination status of children was 
explored over time, distinguishing between the before and after PCV introduction periods of the 
KEPI. The proportion of children who were delayed in their vaccination schedules was examined 
descriptively across three periods: 1) prior to PCV introduction (2007-2010), 2) during the year 
in which PCV was introduced (2011), and, 3) the period following PCV  introduction (2012-
2015). To explore the influence of new vaccine introduction on the dose-specific timeliness of 
routine immunization, segmented binomial regression using generalized estimating equations 
was used comparing the pre-introduction period (2007-2010) to the post-introduction period 
(2012-2015). To maintain balance in the period comparisons, only data from four years before 
and after the introduction of PCV were used in the models. Acknowledging the limited data 
availability to control for potential time-dependent confounders, we only sought to explore the 
association in terms of a time-dependent level change as opposed to changes in the trend 
trajectory, or slope defining the estimated prevalence of delayed vaccination receipt over time.  
Prevalence ratios reflecting pre- and post-introduction period level changes with robust standard 
errors were calculated, accounting for correlation due to approximately 30% of children residing 
in the same household unit as other families with children in the sample. Models included a term 
to control for annual trends in the outcome, given changes to the annual age-eligible catchment 
sample. Individual level factors that were hypothesized to influence the timeliness of vaccine 




adjust models, including household wealth status, ethnicity, and study setting. All analyses were 
conducted using Stata V16.1 in July of 2020. 
 
Results 
From January 2003 to December 2015, the NUHDSS registered 13,563 children one year 
of age living in Viwandani and Korogocho.  Overall, 69.9% of the  children who were 12-23 
months at the time of interview had a vaccination card available for review at one or more 
interviews during this period (Figure 4-1). The distribution of characteristics based on inclusion 
criteria of having a vaccination card was relatively well-balanced between children included 
(n=9,449) and children excluded (4,114) for the entire 2003-2015 surveillance period, though the 
proportion of children who had a card available at the time of interview varied year to year (min: 
44% in 2010, max: 83% in 2012) and children with vaccination cards available were members of 
marginally wealthier households (Table 4.2). More children with vaccination cards were 
members of the Kikuyu ethnic group (26%) than any other ethnicity (Luhya: 19%; Luo:20%; 
Kamba 19%; Kissii:6%; Other:11%), and an equal proportion of male and female children had 
vaccination histories recorded in both surveillance sites (Table 4.2). 
Vaccination history from 5,341 children was recorded during the analytic period of 
interest (36% in the pre-introduction era [2007-2010]; 19% in the year of introduction [2011] and 
45% in the post-introduction era [2012-2015]). The distribution of demographic factors did not 
vary substantially across these three periods (Table 3.3) whereas a higher proportion of children 
were reported as being in the poorest wealth quintile in 2003-2006 period. These years were 
excluded from further analysis to balance the size of the sample for the before and after periods 




three time periods. More than one-quarter of children were members of the richest households in 
the two communities for the same period. Just by showing an immunization card, and therefore 
likely representing children of families who have access to immunization services, the uptake of 
vaccination based on documented history or recall at time of interview was predictably high: 
BCG >98%; DPT1> 97%; DPT2> 94%; and DPT3> 90%. However, the proportion of children 
covered with OPV and measles varied across the three time periods; and fewer than three-
quarters of children were reported as having completed their basic immunization schedule (Table 
4.3). Additionally, age-appropriate vaccination coverage for each vaccine, defined as the 
proportion of children who received each vaccine dose by the recommended age, was low across 
all vaccines doses and time periods. 
 Among children who had date verification of vaccination on their immunization cards, 
many were vaccinated >4 weeks after the recommended age (Table 4.4). From 2007-2015, 
delayed vaccination as a proportion of all children vaccinated during the period was 13.8% for 
BCG recommended at birth, 18.2% and 20.8% for DPT3 and OPV3 recommended at 14 weeks, 
and 54% for Measles recommended at 9 months. With the notable exception of persistent delays 
in measles vaccination, the overall proportion of delayed vaccination across the schedule 
declined most years from 2007 to 2015.  Delayed vaccination was slightly more common in 
Korogocho than Viwandani, particularly for DPT and OPV (25% vs 12% for DPT3 and 29% vs 
13% for OPV3). Children whose families self-reported as Luhya or Luo ethnicities had higher 
levels of delays than the majority ethnic group (Kikuyu).  The distribution of delays skewed 
much higher in the poorest households compared to the richest, across all vaccination encounters 
(Table 4.4). While the prevalence of delays in receipt of BCG, DPT1-3, and OPV1-3 was not 




months was documented consistently in more than 50% of children across sociodemographic 
strata, besides the slight declines observed for the most recent years included from the 
surveillance system (48% in 2014 and 38% in 2015). Of note, the median age of children who 
received delayed vaccination (summarized in Supplemental Table 4.1) did not change 
substantially over time. A small proportion of children were documented as having received 
recommended vaccines a year a more after the recommended age (Supplemental Table 4.2).  
Controlling for calendar year of the interview, there was a statistically significant lower 
prevalence of delayed vaccination observed in the sample, comparing delays in the post-
introduction period (2012 to 2015) to the pre-introduction period (2007-2010) for doses 
administered at birth, 6 weeks, 10 weeks and 14 weeks (results not shown). Delays in measles 
receipt, the last dose recommended in the schedule, showed a significant level change in the 
prevalence of delay in the years following the introduction of PCV compared to the period 
during pre-introduction (Prevalence Ratio [PR]: 0.93; 95% Confidence Interval [95CI]: 0.87-
0.99). After adjusting for surveillance area, ethnicity and wealth, the prevalence ratio of 
vaccination delay in the post-introduction era compared to the pre-introduction era was slightly 
attenuated, though the association suggests lower prevalence of delays in the post-introduction 
period for BCG, DPT1 and DPT3 (Table 4.5). Dissimilar to the unadjusted model, after adjusting 
for surveillance area, ethnicity, and wealth, the prevalence of measles vaccine delays was higher 
in the post-PCV period than the pre-PCV period, though this difference was not statistically 
significant (Table 4.5).   
Discussion  
The introduction of PCV, as well as other vaccines such as RV and more recently IPV, 




progress for immunization services and child health in Kenya. However, new vaccine 
introduction also imposes substantial, long-term financial commitments on ministries of health 
once vaccines like PCV and RV are adopted for routine use.  Evidence that these newly 
incorporated vaccines do not result in disruption or deterioration of other routine immunization 
services is paramount in settings that must balance the desire to innovate with the need for 
continued investment in improving immunization coverage and timeliness overall. In this study, 
using a quantitative approach, we found that new vaccine introduction was not associated with 
any significant decreases in the timeliness of routine immunization services in two urban, poor 
communities in Nairobi.  
While our comparative assessment of routine immunization timeliness between the periods 
before and after PCV introduction were to serve as illustrative of the influence of new vaccine 
introduction generally, our findings may contribute to the case for sustaining PCV in the routine 
schedule going forward. Kenya, like many LMICs, introduced new vaccines into the routine 
schedule with the support of co-financing from Gavi, the Vaccine Alliance, a public-private 
partnership created to improve access to new and under-utilized vaccines in the world’s poorest 
countries.2 Gavi’s funding agreements are designed to be time bound with a view to ‘graduate’ 
country immunization programs from donor support and transition them to a fully self-financed 
model, using domestic resources to pay for the purchase and delivery of new vaccines. Countries 
subscribing to this financial model assume the full cost of new vaccines after the 3-year average 
gross national income per capita (GNIpc) exceeds US$1580.25 Using GNIpc projections for the 
current decade, Kenya is slated to complete its transition and become financially responsible for 
sustaining the inclusion of PCV as soon as 2027 along with other newly adopted vaccines (i.e. 




use of PCV in the routine schedule may take into account how the new vaccine program fits with 
the overarching goals of the KEPI to achieve high, on-time coverage of routine vaccines.  
Decisions about the introduction of new vaccines into the routine immunization schedule are 
generally made at the central government level, and the responsibility of rollout is held with local 
health authorities. It is for this reason that studying the potential systems shocks of changes to 
the immunization schedule at more localized levels is important for identifying and addressing 
any challenges, particularly among target children who are at higher risk for premature death due 
to their living conditions and circumstances.8,27 To our knowledge, this study is the first to show 
that following recent new vaccine introduction in a local setting, timeliness of other routine 
immunization slightly improved, or remained neutral to the presence of additional vaccines in the 
schedule.  Without accompanying qualitative understanding of the reception of new vaccines by 
the communities residing in Korogocho and Viwandani, we cannot further substantiate the 
association; and the comparative prevalence ratios may actually capture aggregate average 
declines in delayed vaccination that initiated well before PCV introduction in 2011. Nonetheless, 
the fact that we did not observe any substantial spikes or large prevalence ratios comparing 
delayed vaccination in the preceding and after periods of PCV introduction is evidence to say 
that the delivery of routine immunization services did not experience disruption or deterioration 
associated temporally with the incorporation of new vaccines in Korogocho and Viwandani. 
Much like findings from previous research on vaccination coverage and completion in 
Korogocho and Viwandani, our assessment of delayed vaccination over time in the two 
communities underscores the extent to which children are under-immunized and are at sustained 
risk of vaccine-preventable diseases. In 2015, fewer than three-quarters of children were 




intervenable differences to close the gap between children with complete and incomplete 
immunization schedules, found that children who had not completed their schedules by 12 
months of age were frequently delayed in one or more doses of their vaccination schedule.28 
With up to 50% of our sample being delayed in their measles vaccination, there undoubtedly is 
an impact on children completing their schedules and more importantly achieving protection 
against the VPDs targeted by the KEPI within their most vulnerable year of life before the first 
birthday.  
When compared to estimated delayed vaccination at the national-level, children in 
Korogocho and Viwandani, had substantially higher levels of delayed measles vaccination, 54% 
overall for the study period compared to an estimated 28% nationwide in 2014.29 Delayed 
vaccination for other routine doses in Korogocho and Viwandani was lower than the national 
estimates (BCG: 13.8% vs. 24.3%; DPT1: 8.1% vs. 10.6%; DPT2: 12.6% vs. 18.1%; DPT3: 
18.2% vs. 24.7%), though there were significant differences in the proportion of delayed 
vaccination across socioeconomic strata in our study, with the proportion of children delayed in 
their vaccination being much higher for minority ethnic groups and lower wealth strata. In 
contrast, delays in measles vaccination persisted across time and social determinants in both 
communities. This is particularly concerning in an urban, slum setting where vaccine-
preventable disease transmission intensity is likely higher, coupled with the influence of migrant 
effects, other food security and sanitation risks, posing serious challenges for childhood 
survival.27   
Evaluating program changes using quantitative methods often suffers from bias due to 
unobserved confounding and heterogeneity in study samples. This study which compared delays 




vaccines is subject to the same type of methodological concern. Nonetheless, we have not sought 
to determine causal associations, rather define from an evaluation perspective that there were no 
large increases in the proportion of children receiving delayed vaccination following the first 
new vaccine introduction of recent introductions. We were not able to control for additional 
factors that may have a time-specific association with vaccination timeliness, such as anti-
vaccine media campaigns, vaccine supply stock-outs, or supplementary immunization activities. 
A second important limitation to our study is the exclusion of children who did not have a 
vaccination card at the time of interview. The proportion of children who had a card available at 
the time of interview was not stable over time, ranging from 83% in 2012 to 44% in 2010. If 
children without vaccination cards discarded or lost them upon completing their schedules on-
time, then our findings may over-estimate the extent of the risk that delayed vaccination poses to 
these two communities. However, it is more likely that the lack of a vaccination card represents 
an access barrier to immunization services and the exclusion of children without cards may 
under-estimate the true prevalence of delays, or even non-vaccination. A longitudinal 
surveillance platform like the NUHDSS is a worthwhile investment by governments and donors 
to ensure that health needs are being met in communities that lack coverage of health services 
and attention from national-scale death registries. However, the setting in which the NUHDSS 
operates is a challenge to complete follow-up. The average in-migration for children under-five 
is 36.9% annually, whereas the average out-migration is 31.4%.19 This circular migration pattern 
is an obstacle to obtaining complete immunization records for all births registered in the system 






In two urban, informal settlements, the introduction of new vaccines was not associated 
with significantly higher prevalence of delayed vaccination in the routine immunization program. 
With a large concentration of the urban population residing in informal settlements in Nairobi, 
on-time and up-to-date vaccination is essential for continued progress towards improving 
childhood health among the most vulnerable. New vaccine introduction might be a used to 
rejuvenate program goals, increasing coverage to more diseases and improving the uptake and 






Table 4.1 Cut-offs for on-time vaccination according to age-specific recommendations in the 
Kenyan Expanded Programme on Immunization (KEPI)* 
Age at 
administration 
Vaccines Minimum acceptable 
age (in days) 
Delays initiated  
(age in days) 
Birth BCG, OPV0 0  ≥ 31 
6 weeks Penta1, OPV1 42  ≥ 72 








9 months Measles 252  ≥ 282 
*PCV introduced in 2011 and RV in 2014. Both vaccines are recommended at 6 and 10 weeks, 






Table 4.2 Characteristics of children 12-23 months identified in NUHDSS (2003-2015) according to 
the availability of a vaccination card 
 Overall Card Recall 
 Frequency (%) 
Total 13,563(100%) 9,449 (100%) 4,114 (100%) 
Surveillance site    
  Korogocho 6,720 (50%) 4,934 (52%) 1,786 (43%) 
  Viwandani 6,843 (50%) 4,515 (48%) 2,328 (57%) 
Gender    
  Male 6,883 (51%) 4,180 (51%) 2,073 (50%) 
  Female 6,680 (49%) 4,639 (49%) 2,041 (50%) 
Ethnicity    
  Kikuyu  3,544 (26%) 2,464 (26%) 1,080 (26%) 
  Luhya  2,464 (18%) 1,755 (19%) 709 (17%) 
  Luo  2,638 (19%) 1,880 (20%) 758 (18%) 
  Kamba 2,703 (20%) 1,829 (19%) 874 (21%) 
  Kissii  766 (6%) 507 (5%) 259 (6%) 
  Other 1,448 (11%) 1,014 (11%) 434 (11%) 
Wealth quintile    
  Poorest 2,328 (17%) 1,540 (16%) 788 (19%) 
  Poor  2,347 (17%) 1,551 (16%) 796 (19%) 
  Middle 2,568 (19%) 1,766 (19%) 802 (19%) 
  Rich 3,060 (23%) 2,136 (23%) 924 (22%) 
  Richest 3,260 (24%) 2,456 (26%) 804 (20%) 
Year    
  2003 2,155 (16%) 1,338 (14%) 817 (20%) 
  2004 1,624 (12%) 1,175 (12%) 449 (11%) 
  2005 1,093 (8%) 751 (8%) 342 (8%) 
  2006 1,242 (9%) 888 (9%) 354 (9%) 
  2007 820 (5%) 519 (5%) 301 (7%) 
  2008 1,142 (9%) 879 (9%) 263 (6%) 
  2009 709 (3%) 324 (3%) 385 (9%) 
  2010 511 (2%) 224 (2%) 287 (7%) 
  2011 1,285 (9%) 1036 (11%) 250 (6%) 
  2012 1,542 (11%) 1273 (13%) 259 (7%) 
  2013 916 (7%) 728 (8%) 188 (5%) 
  2014 521 (4%) 297 (3%) 224 (5%) 










Period prior to new 
vaccine intro 
(2007-2010) 
Period during new 
vaccine intro  
(2011) 
Period after new 
vaccine intro 
(2012-2015) 
 n = 4108 n = 1905 n = 1031 n = 2405 
Age     
  in months, mean 15.76 15.72 16.40 15.13 
Study site     
  Korogocho 56.4% 46.3% 52.3% 49.7% 
  Viwandani 43.6% 53.7% 47.7% 50.3% 
Gender     
  Male 50.9% 49.8% 51.7% 51.4% 
  Female 49.1% 50.2% 48.3% 48.6% 
Ethnicity     
  Kikuyu  25.9% 27.2% 28.0% 24.7% 
  Luhya  16.7% 20.1% 18.0% 20.8% 
  Luo  23.7% 17.6% 17.6% 16.3% 
  Kamba 17.3% 21.4% 21.0% 20.6% 
  Kissii  4.5% 6.1% 4.8% 6.5% 
  Other 12.0% 7.7% 10.7% 11.1% 
Wealth quintile     
  Poorest 21.3% 14.0% 11.1% 11.8% 
  Poor  16.2% 16.6% 18.4% 15.8% 
  Middle 18.1% 18.4% 20.1% 19.3% 
  Rich 20.8% 23.3% 21.3% 25.7% 
  Richest 23.6% 27.6% 29.1% 27.5% 
Vaccines received*     
  BCG 99.8% 99.6% 98.6% 97.3% 
  DPT1 99.0% 98.5% 97.8% 97.0% 
  DPT2 97.4% 97.4% 95.2% 94.1% 
  DPT3 94.8% 94.4% 89.9% 90.7% 




  OPV2 96.9% 96.8% 93.3% 93.9% 
  OPV3 94.0% 94.3% 87.1% 90.9% 
  Measles 85.9% 85.9% 78.0% 73.8% 
  All (by 12 months of 
age)** 76.3% 72.5% 66.3% 62.5% 
 
* based on both recall and card record of vaccination 
** “all” or fully immunized child coverage includes only children who had card record for all vaccines as denominator in order to 
verify receipt by 12 months of age for all vaccines: n=3,030 for excluded period; n = 1,512 for pre-introduction period; n = 958 for 





Table 4.4 Prevalence of delayed vaccination in children 12-23 months registered in the NUHDSS before, during and after PCV 
introduction according to demographic factors 
 BCG DPT1 DPT2 DPT3 OPV1 OPV2 OPV3 Measles 
 
% delayed (total frequency) 
Overall delay 13.8% (5219) 8.1% (5131) 12.6% (4962) 18.2% (4705) 11.4% (5101) 15.6% (4917) 20.8% (4621) 54.0% (3811) 
Study site                 
  Korogocho 15.3% (2563) 10.5% (2494) 17.0% (2378) 25.0% (2213) 15.2% (2470) 21.6% (2345) 29.3% (2150) 55.5% (1691) 
  Viwandani 12.3% (2656) 5.7% (2637) 8.4% (2584) 12.1% (2492) 7.8% (2631) 10.2% (2572) 13.4% (2471) 52.8% (2120) 
Gender                 
  Male 13.6% (2664) 8.7% (2611) 13.3% (2520) 18.7% (2375) 11.6% (2587) 15.7% (2505) 21.1% (2329) 54.5% (1935) 
  Female 13.9% (2555) 7.4% (2520) 11.8% (2442) 17.6% (2330) 11.1% (2514) 15.6% (2412) 20.5% (2292) 53.5% (1876) 
Ethnicity                 
  Kikuyu  8.9% (1369) 5.2% (1348) 7.5% (1322) 12.6% (1265) 9.7% (1337) 12.6% (1306) 17.4% (1240) 51.0% (1006) 
  Luhya  20.6% (1045) 12.3% (1038) 19.6% (1001) 26.3% (947) 15.3% (1030) 20.9% (990) 27.5% (932) 54.8% (786) 
  Luo  18.3% (895) 9.9% (865) 16.7% (810) 23.9% (752) 13.3% (860) 20.2% (801) 27.6% (736) 52.9% (569) 
  Kamba 10.3% (1092) 5.0% (1080) 7.6% (1060) 12.1% (1022) 7.2% (1077) 9.9% (1056) 13.6% (1007) 53.0% (869) 
  Kissii  9.1% (309) 6.2% (308) 9.5% (304) 11.6% (293) 7.8% (308) 10.9% (304) 11.5% (287) 58.8% (257) 
  Other 15.1% (509) 11.6% (492) 17.8% (465) 25.4% (426) 15.3% (489) 21.3% (460) 27.7% (419) 62.0% (324) 
Wealth 
quintile                 
  Poorest 17.7% (651) 11.2% (633) 15.5% (612) 21.4% (579) 14.0% (637) 18.4% (609) 25.3% (570) 54.8% (473) 
  Poor  14.9% (863) 7.9% (857) 13.7% (827) 19.5% (780) 11.4% (853) 17.2% (821) 22.6% (769) 55.4% (643) 
  Middle 15.8% (998) 8.8% (980) 13.3% (945) 20.0% (887) 12.8% (974) 17.7% (930) 23.8% (858) 57.1% (718) 
  Rich 11.9% (1251) 7.8% (1234) 11.5% (1194) 16.6% (1134) 10.6% (1220) 14.1% (1186) 18.1% (1119) 51.9% (919) 
  Richest 11.5% (1456) 6.5% (1427) 11.0% (1384) 16.1% (1325) 9.8% (1417) 13.4% (1371) 18.2% (1305) 52.6% (1058) 
Year                 
  2007 27.1% (513) 10.9% (497) 15.1% (483) 25.0% (452) 16.2% (495) 19.9% (473) 28.1% (431) 57.4% (345) 
  2008 16.9% (856) 9.8% (819) 15.5% (785) 21.9% (744) 14.9% (813) 22.1% (777) 29.0% (724) 57.3% (623) 
  2009 19.9% (302) 13.8% (297) 18.6% (290) 27.3% (271) 13.9% (296) 17.4% (287) 27.5% (276) 58.0% (231) 
  2010 16.0% (212) 10.7% (205) 14.4% (202) 19.7% (183) 9.3% (205) 11.9% (201) 22.1% (190) 52.8% (159) 
  2011 10.4% (1011) 6.8% (1001) 11.7% (967) 17.6% (907) 13.1% (984) 18.4% (946) 22.7% (867) 50.6% (770) 
  2012 8.4% (1227) 5.8% (1229) 9.8% (1183) 13.6% (1128) 7.2% (1223) 10.7% (1186) 14.3% (1136) 55.4% (909) 
  2013 11.7% (683) 6.4% (672) 10.5% (649) 14.4% (625) 8.1% (675) 11.0% (646) 14.7% (612) 54.2% (450) 
  2014 13.4% (291) 9.0% (289) 12.3% (285) 16.3% (282) 12.9% (287) 15.2% (283) 16.8% (273) 48.4% (225) 




                 
Children                 
with date on    
card 
(denominator) 5219  5131  4962  4705  5101  4917  4621  3811  
who received 
vaccine 5254  5218  5098  4907  5202  5065  4879  4214  
who did not 
receive 
vaccine 87  123  243  434  139  276  462  1127  
Total 5341  5341  5341  5341  5341  5341  5341  5341  
 





Table 4.5 Multivariable associations between time period (2007-2010 versus 2012-2015) and delays in vaccination for doses at birth, 6 
weeks, 14 weeks and 9 months of age among children 12-23 months registered in the NUHDSS 
 Prevalence ratios (95% CI) 
ref = on-time vaccination  
 BCG (birth) DPT1 (6 weeks) DPT3 (10 weeks) Measles (9 months) 
Period  
(ref = pre [2007-2010])         
  Post (2012-2015)  0.67 (0.45-0.99) 0.41 (0.24-0.69) 0.59 (0.41-0.83) 1.19 (0.99-1.42) 
Surveillance site  
(ref = Korogocho)         
  Viwandani 0.89 (0.86-1.02) 0.64 (0.51-0.80) 0.56 (0.48-0.66) 0.93 (0.086-0.99) 
Ethnicity  
(ref = Kikuyu)         
  Luhya  2.21 (1.76-2.78) 2.50 (1.83-3.40) 2.20 (1.79-2.69) 1.06 (0.97-1.17) 
  Luo  2.04 (1.61-2.58) 1.91 (1.37-2.67) 1.88 (1.51-2.33) 1.00 (0.90-1.12) 
  Kamba 1.26 (0.96-1.65) 1.30 (0.88-1.92) 1.28 (0.99-1.66) 1.05 (0.95-1.16) 
  Kissii  1.15 (0.76-1.74) 1.64 (0.95-2.84) 1.35 (0.91-2.01) 1.15 (1.00-1.32) 
  Other 1.78 (1.32-2.39) 2.32 (1.58-3.40) 2.01 (1.56-2.57) 1.17 (1.04-1.31) 
Wealth quintile  
(ref = poorest)         
  Poor  0.86 (0.67-1.10) 0.73 (0.51-1.04) 0.83 (0.66-1.04) 1.02 (0.90-1.14) 
  Middle 0.85 (0.67-1.08) 0.84 (0.60-1.16) 0.93 (0.75-1.15) 1.06 (0.94-1.18) 
  Rich 0.76 (0.60-0.96) 0.80 (0.58-1.10) 0.76 (0.61-0.94) 0.97 (0.86-1.08) 
  Richest 0.68 (0.54-0.87) 0.66 (0.47-0.91) 0.70 (0.57-0.87) 0.94 (0.84-1.05) 
         










OPV1 at 6 
weeks 
OPV2 at 10 
weeks 
OPV3 at 14 
weeks DPT1 at 6 weeks 
DPT2 at 10 
weeks DPT3 at 14 weeks 
Measles at 9 
months 
 >28 days ≥72 days ≥100 days ≥128 days ≥72 days ≥100 days ≥128 days ≥282 days 
 n = 719 n = 579 n = 769 n = 961 n = 414 n = 623 n = 854 n = 2058 
2007 43 (25) 89 (41) 121 (94) 157 (66) 87 (31) 118 (29) 152 (54) 298 (37) 
2008 47 (36) 95 (39) 119 (44) 150 (57) 92 (94) 130 (75) 158 (72) 296 (27) 
2009 50.5 (86) 92 (40) 123 (50) 162 (80) 92 (39) 124 (51) 161 (88) 301 (49) 
2010 57 (323) 89 (327) 127 (52) 153 (70) 107 (333) 127 (53) 153 (52) 298 (22) 
2011 50 (41) 116 (211) 122 (58) 160 (74) 92 (131) 117 (39) 155 (63) 301 (34) 
2012 46 (38) 174 (307) 116 (34) 147 (57) 82 (44) 114 (31) 143 (33) 301 (36) 
2013 48 (79.5) 141 (330) 124 (114) 155 (62) 129 (328) 131 (114) 150 (50) 299 (28) 
2014 69 (330) 244 (331) 113 (82) 149 (69) 108 (331) 118 (271) 149 (76) 298 (29) 
2015 64.5 (325) 109 (152) 124 (155) 153 (71) 153 (118) 137 (155) 156 (179) 292 (47) 






OPV1 at 6 
weeks 
OPV2 at 10 
weeks 
OPV3 at 14 
weeks DPT1 at 6 weeks 
DPT2 at 10 
weeks DPT3 at 14 weeks 
Measles at 9 
months 
 >28 days ≥72 days ≥100 days ≥128 days ≥72 days ≥100 days ≥128 days ≥282 days 
 n = 719 n = 579 n = 769 n = 961 n = 414 n = 623 n = 854 n = 2058 
2007 533 584 614 540 584 614 540 609 
2008 511 653 596 625 653 596 625 664 
2009 623 661 674 511 661 674 490 656 
2010 428 449 463 462 453 449 437 425 
2011 690 439 512 544 447 448 512 679 
2012 506 538 566 601 538 566 601 644 
2013 398 786 575 607 426 575 607 1006 
2014 733 1139 469 483 441 471 544 564 





Figure 4-1 Study sample diagram of children 12-23 months registered in NUHDSS from 2003-2015 
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Chapter 5 Discussion and Concluding Reflections 
 
This dissertation examined aspects of immunization completion and timeliness in sub-
Saharan Africa, using data from Demographic and Health Surveys in several countries and data 
from a demographic surveillance site in Nairobi, Kenya. In this chapter, the findings from the 
three research aims are reviewed in the context of each other and other published literature. 
Then, the strengths and limitations of the research approach overall, including the methods as 
well as conceptualization and design of the research itself, are discussed along with proposed 
future areas of research that merit further inquiry. Finally, this chapter concludes with a summary 
of implications for immunization programs. 
Aims 1 and 2: Using Demographic and Health Surveys to examine matters of immunization 
timeliness and completion 
 
In aims 1 and 2, DHS data from the same set of sub-Saharan African countries were used 
to investigate two considerations of immunization performance that have been overlooked in the 
operational research literature: (1) the relationship between dose-specific delays in the basic 
immunization series and overall completion rates by 12 months of age; and (2) the relationship 
between burden of under-five death and vaccination outcomes, defined as being fully immunized 
with the basic schedule by the time of the interview. Both aims sought to investigate 
programmatic topics that have implications for concentrating the risk of vaccine-preventable 
disease transmission and morbimortality.  
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For the first aim, using only data from children who had vaccination records available at 
the time of interview, dose-specific delays at any interval in the schedule were associated with 
substantially lower likelihood of completing the schedule by 12 months of age. The large 
proportion of children who either received their BCG birth dose  late (25%) or delayed the 
initiation of their three dose series of pentavalent (23%) were the driving force in determining 
subsequent delays in the series and non-completion by age 12 months. . 
Overall, the proportion of children who had not completed their recommended vaccines 
in their first year of life was 57%, which varied substantially by country from as high as 73% in 
Gabon to 12% in Burundi. There did not appear to be a threshold at which delays did not matter 
for completing the schedule across countries. That is, even in countries with fewer children 
failing to complete their schedules, delays mattered for predicting incompletion rates.  It is 
expected that the relationship between late vaccination and subsequent delays is semi-fixed, 
owing to the minimal 4 week interval required  between vaccination doses  to elicit an optimal 
immune response, effectively maximizing protection.1 In this sense, our study evidences the 
programmatic implications of losing children in follow-up, when delays are prolonged and 
children fail to receive subsequent doses and, as a result, only achieve partial protection against 
vaccine-preventable diseases. 
Delayed vaccination measured as a continuous number  of days or weeks that have 
elapsed since the target age for vaccination has been studied in several populations in sub-
Saharan Africa (SSA). These studies have typically sought to estimate the effective coverage at 
age intervals in weeks or months following the recommended age for vaccination, graphically 
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depicting the difference in coverage assumed counting any dose administered, irrespective of age 
at vaccination, and the coverage achieved at each age-specific interval using the inverse Kaplan-
Meier survival estimator.2,3 These age-specific coverage estimates highlight the extent to which 
children are not protected at the ages targeted by vaccine recommendations  – usually the earliest 
age at which safety and efficacy has been demonstrated in clinical trials. However, examples 
such as Clark & Anderson 2009 evidenced that many children who were not vaccinated on-time 
were eventually brought up to date in their schedules in later childhood. These studies 
overlooked the analytic opportunity to evaluate the dose-specific association of delays with drop-
out from the immunization schedule. From a programmatic perspective, identifying the total 
burden of delayed vaccination in a population and its relationship with driving under-vaccination 
at 12 months of age is helpful for designing strategies to address the delays that occur at specific 
dose intervals most frequently, keeping families and their children on-track in their schedules. 
Periodic intensification of routine immunization (PIRI) through outreach campaigns, carrying 
children forward in immunization registries until spontaneous demand brings them to health 
centers, and missing opportunities to offer protection against vaccine-preventable diseases are all 
implications of delayed vaccination that consume substantial scarce resources for health. 
In aim 2, we used birth histories and childhood vaccination data, including maternal 
recall and card verification, to examine the association between having experienced the death of 
a child and vaccination outcomes in surviving children among families. We found a weak 
association between families having experienced the death of a young child  and poor 
vaccination outcomes among subsequent births.. Our guiding hypothesis was that mothers who 
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experience the premature death of a child under-five would make health choices that favored 
child survivorship such as immunization. The findings did not support this hypothesis, but it is 
possible that the hypothesis did not have a clear footing in knowledge regarding behavior change 
and motivation-driven agency in areas characterized by substantial access disadvantages. Only 
one other study that we could find in the sub-region, in Nigeria, evaluated the influence of 
preceding childhood death on subsequent health service utilization patterns among mothers. 
Though not directly comparable to our outcome measuring vaccination utilization, the authors 
also found lower likelihood of utilization (postnatal care: OR 0.64, 95%CI 0.57-0.71; skilled 
birth attendant: OR 0.56; 95%CI 0.50-0.63; postnatal care: OR 0.65, 95%CI 0.55-0.69) in 
women who experienced the death of a child compared to those who did not. After adjusting for 
socioeconomic differences, the significance of the relationship did not hold, and the authors 
concluded there was no association between child death and maternal health service utilization. 
Their study . 
One explanation for the findings in our study and those from the Nigerian study that   
were not in line with our hypothesis could be that women who experience 100% survivorship of  
their children, which was used for the index, are not appropriate comparators for evaluating the 
influence of child death, with so many unobserved or unmeasured confounding factors. Instead, 
the closest counterfactual for evaluating the relationship between  mothers’ decisions and 
motivations to vaccinate their children following exposure to a child death might be comparing 
survivorship status of births vaccination outcomes among subsequent births within the same 
mother. That is, among women who have 3 or more births, modelling the per-woman likelihood 
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of her child being vaccinated following the death of a preceding child’s death compared to 
vaccination outcomes following the  the survival of other births. Since the DHS only collects 
data on vaccination for 3-5 years prior to the survey,  the eligible population of women with at 
least 3 non-multiple births is very small or does not exist in some countries. This, however, could 
be evaluated using demographic surveillance systems like the NUHDSS because of their ability 
to longitudinally follow mothers and their children’s outcomes. 
Most recent research on vaccination  describes  uptake and timeliness patterns, or 
evaluates predictors for ensuring both, , as opposed to a focus on under-vaccination and barriers 
to immunization.4–6 Yet, strategic goals and plans are often framed around objectives for 
increasing access to immunization among the ‘hard-to-reach’ and ‘vulnerable’ populations. It is 
generally assumed that children who are under-vaccinated or non-vaccinated are more 
vulnerable, although this term is poorly defined for program intervention and in research.7 
Scenarios in which under-vaccinated or non-vaccinated children reside in the same geographic 
area are a substantial challenge for immunization programs. Despite efforts to increase aggregate 
coverage to high thresholds, under-vaccinated populations that cluster together and have limited 
interaction with vaccinated populations, have elevated spatial-specific risk for acquiring vaccine-
preventable diseases. In this sense, there is a continued need to understand the mechanisms that 
doubly disadvantage children due to spatial risk of U5M and under-vaccination. 
Aims 3: Using the Nairobi Urban Health and Demographic Surveillance System to assess the 




In the third aim of this dissertation, the annual prevalence of vaccination delays was 
evaluated before and after the introduction of PCV in two urban informal settlements in Kenya, 
Nairobi. Kenya adopted both PCV and RV, vaccines against childhood pneumococcal disease 
and rotavirus, in the early and mid-2010s. Like many low-middle income countries in the region, 
Kenya leveraged donor support to subsidize the procurement of these new vaccines and roll them 
out for routine use. These vaccines were delivered as part of the national immunization program, 
using the same operational resources and systems available to administer other routine childhood 
vaccines.8 We found that there were no significant differences in the average prevalence of 
delayed vaccination before and after the introduction of PCV in 2011; however, the prevalence 
of delays in these two communities was persistently high over time and unchanged in the years 
following new vaccine introduction. Notably, the proportion of children vaccinated by 4 or more 
weeks late with measles was greater than 50% in most years.  
Immunization programs balance the competing priorities of improving coverage and 
timeliness of routine vaccination while also re-training their workforce to learn new schedules, 
contraindications, and administration techniques to support the introduction of new vaccines. 
Our study on the impact of new vaccine introduction for routine services in an urban, poor 
population underscores that systems were prepared to incorporate new vaccines, at least when 
co-administered with other doses in the existing schedule, but resources used to invest in new 
vaccines may have detracted from investment to scale-up coverage and improve the timeliness of 
vaccination. Other researchers have come to similar conclusions from studying trends in 
aggregate coverage over time of traditional vaccines in the routine schedule before and after 
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introduction of new vaccines.9 Our study is the first to consider any changes to timeliness of 
vaccination that occurred following the introduction of new vaccines for routine use in a poor, 
urban area.  
A recently published analysis assessed the correlation between levels of donor financing 
and changes in vaccination coverage across a set of development assistance eligible countries. 
Consistent with our findings and others,  development assistance, including from Gavi – the 
primary driver of new vaccine introduction in low- and middle-income countries, has  not 
contributed to declines in coverage for traditional vaccines, whereas coverage for new vaccines 
has substantially improved in these countries during the same time period..10 New vaccine 
introduction is often accompanied by investment to expand cold chain systems, develop targeted 
communication and education about the new antigens, and carry out social mobilization 
activities. However, these resources from Gavi and other donorsmay not translate to improving 
the overall outcomes of the immunization system. Going forward, especially as countries prepare 
to assume more financial responsibility in their cost-sharing agreements11, considerations for 
renewed investment in routine services will be needed. 
Strengths, limitations, and future directions  
Our approach to studying issues of vaccination timeliness differed from approaches used in 
previous research that were more focused on describing timeliness and coverage. In considering 
how vaccination timeliness influences or facilitates other program outcomes, such as completion 
of the basic schedule, we were able to articulate more concrete recommendations for targeting 
resources or interventions. Nonetheless, the aims in this dissertation that use categorical 
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classification of vaccination timeliness do so without clear consensus on cut-offs for defining on-
time versus delayed vaccination. We considered delayed vaccination as any dose administered 4 
weeks or more after the recommended age. Other studies on the timeliness of vaccination in low- 
and middle-income countries (LMIC) have used lower threshold cut-offs for on-time versus 
delayed, at 1 or 2 weeks after the recommended age.12 There clearly is a need for consensus in 
order to facilitate comparisons across studies; however, more than consensus, defining timeliness 
based on the underlying known disease mechanisms and implications for vaccine-derived 
protection associated with late or early vaccination should be more consistently applied. Due to 
differences in childhood nutritional status, the local epidemiological profile of vaccine-
preventable diseases, and the prevalence of breastfeeding across countries, vaccination timeliness 
may have differing degrees of influence on improving protection against vaccine-preventable 
diseases between and within countries. For example, the timing of rotavirus vaccination is 
subject to age-restrictions that reduce the potential risk of adverse outcomes such as 
intussusception, but there is also evidence that earlier or later vaccination in infancy, depending 
on the context, might result in better immune responses.13,14 For future studies, the focus of 
estimating the health impact and disease implications of delayed vaccination should be 
prioritized.  
In our work, the programmatic definitions used to derive variables on delayed vaccination  
were used in line with how immunization programs categorize timeliness. However, 
misclassifying children’s vaccination status, either for assessing timeliness, coverage, or 
completion of the basic schedule, due to recall or reporting errors is a real concern. We 
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ascertained vaccination status using only review of paper-based records for aims 1 and 3, 
excluding a sizeable proportion of children who had lost or never had a vaccination card (in aim 
1, ~40%). This type of selection bias is a well-recognized data collection and study design 
challenge in the immunization services research space. Some studies have tried to address this 
bias by imputing vaccination status for children without cards from the known distribution of 
values for age at vaccination among children who have cards.2 However, this approach assumes 
that children who do not have cards are similar to children who do have cards. Comparing the 
distribution of covariates in our aim 1, children without cards had mothers who were less 
educated and poorer in comparison to children with cards, and both of these maternal 
characteristics were e associated with low vaccination uptake. Due to this limitation, we cannot 
necessarily generalize findings from studying the timeliness of vaccination in our sample to 
children who do not have documentation of vaccination. We would anticipate that children 
without vaccination cards would show higher prevalence of delays and lower overall completion 
rates, which likely suggests that our estimation of the association between dose-specific delays 
and overall completion rates is conservative. But we cannot assume that the interval-dependent 
prevalence of delays would be same between the included and excluded populations due to 
differences in access to birth delivery in hospitals, among other healthcare use patterns.  
Methodological advancements for treating this type of selection bias in the estimation of age-
specific vaccination coverage and timeliness is an area for future work. To date, most 
applications of correcting for selection bias have been employed in higher-income settings using 
electronic health registry (EHR) data. One example adjusted for incomplete follow-up of the 
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source population in the Spanish EHR (‘Base de datos para la Investigacion 
Farmacoepidemiologica en Atencia Primaria’) using inverse probability weighting methods to 
generate more precise population-based estimates of Human Papillomavirus (HPV) and pertussis 
vaccination coverage.15 Such approaches could be considered for future analyses of the DHS, 
which do not allow calculation of age at vaccination for children without vaccination cards or 
children who have died prior to the interview, as we have already discussed.  
One important benefit of using data from documented vaccination history in health or 
vaccine records is that there are other dates in the document that can be used for validity and 
plausibility inference based on the expected chronological order of event history. The quality of 
data collected by DHS on vaccination records is generally considered good, and in fact used to 
grade administrative coverage reports from countries.16 However, there is always the potential 
that hurried healthcare workers either do not register dates accurately or fail to register any date 
of vaccine administration even though it occurred. There is no gold standard comparator for 
measuring vaccination status, even serological assessment has its drawbacks.17 Home-based 
records, such as vaccination cards, and maternal recall have been found to perform consistently 
well as methods for defining vaccination status.18  
Another important limitation to this dissertation is the level at which data were compiled and 
analyzed, which has implications for drawing conclusions and making practical 
recommendations for immunization programs. First, the scope of aims 1 and 2 included data 
from a vastly diverse set of countries located in the same sub-region, and representative of 
different cultural contexts, levels of public health infrastructure, and types of political structures, 
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all factors that influence the performance of vaccination programs. There were simply too many 
dimensions that country-level models would have needed to consider to appropriately adjust for 
each specific context. Instead, we opted to include fixed effect terms for countries in our pooled 
models to control for unobserved country differences and use the pooled models as a first step in 
exploring the questions posed in aims 1 and 2.  
This approach may have been more suitable for aim 2 than aim 1. In aim 2, we evaluated 
how the death of a young child in a family might influence vaccination patterns in subsequent 
children. Although childhood mortality in SSA has declined, the experience of losing a child 
under-five for mothers and families remains a common event, in terms of the overall proportion 
being high of women who have had a young child die across their lifetime.19 In our study, 20% 
of families (or rather index children) had at least one under-five childhood death in the family 
occur within the 10 years prior to the survey. Due to the commonality of the event, and one that 
does not seem to vary substantially across the sub-region20, it is warranted to explore the 
relationship between child death within families and their communities and vaccination 
outcomes using the multi-country pooled approach. In contrast, the study of vaccination timing 
and completion in aim 1 is highly context dependent and it is considerably more important to 
account for all contextual differences in attempting to interpret the findings outside of the 
original intended scope of demonstrating the relationship between timing and completion. For a 
sensitivity analysis, we estimated country-stratified models to evaluate the association between 
delays in BCG, penta1, and measles vaccination, respectively, and overall completion. The 
average associations at country-level were generally consistent with our pooled estimates, but 
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further investigation into country-specific confounding factors would be needed to develop more 
appropriate recommendations in targeting resources at the local level. This too could be an area 
for future work. 
There is a second limitation regarding the level, or units, analyzed in this dissertation across 
all three aims. Using individual children to study vaccination outcomes is preferred to studying 
aggregate administrative reports that mask heterogeneity in uptake at a more localized level; 
however, we did not take advantage of the granularity of information available to us in the DHS 
and NUHDSS to assess the implication of under-vaccination and non-vaccination clustering. It 
was not an original aim to assess the spatial determinants of timeliness, under-, and non-
vaccination in this dissertation, but the use of geocoded data, where available, to evaluate 
clustered associations between maternal experience with death and vaccination outcomes may 
have been a more appropriate method to isolate and distinguish between the effects of 
community and individual-family experiences with childhood death on vaccination patterns for 
subsequent children. In recent years, DHS and other demographic surveys have made 
georeferenced data more accessible to the public for use in analysis. Future work to identify 
where and how under- and non-vaccinated children are geographically distributed within and 
between lower administrative units across SSA may be an improved indicator for predicting 
local effective protection from vaccination, as opposed to age-specific coverage.  
Implications and significance for public health 
The Sustainable Development Goal (SDG) agenda has ambitiously reframed global 
childhood survival around the goal of reducing under-five deaths to fewer than 25 per 1,000 live 
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births in every country by 2030.21 Even though U5M declined by over 50% during the period 
between 1990-2015, a disproportionate number of childhood deaths still occur in SSA where 
only 25% of the global infant birth cohort is born, yet 50% of all-cause childhood deaths occur.22 
Expanding the reach of immunization programs will play an important role in continued efforts 
to reduce preventable child death and morbidity in the sub-region. 
 Measles vaccination is expected to have the largest impact in continued reduction of the 
global burden of vaccine-preventable disease, with upwards of 56 million under-five deaths 
averted between 2000-2030 in 73 of the poorest countries worldwide based on modelling 
estimation by Gavi’s Vaccine Impact Modelling Consortium. Despite evidence that measles 
vaccination is an essential public health measure for improving child health, especially in rapidly 
urbanizing areas confronting health transitions, the proportion of children who received measles 
vaccine late or not at all in our studies was the highest among all vaccinations in the basic 
schedule. Although not studied in this dissertation, the second dose of measles is available in 
fewer than 25 countries in the sub-region, as of 2015, increasing the importance of attaining 
high, on-time coverage with the single dose available to most children.23  
 The role of poor vaccination timeliness and low completion in pooling of risk for 
vaccine-preventable diseases and potentiating outbreaks associated with poor vaccination 
patterns clustering geographically is increasing attention in research. In practice, administrative 
reports, and programmatic knowledge about the distribution of access disadvantages in the 
community are two important factors that guide the design of outreach, campaign targeting, and 
social mobilization activities. Using collaboration between researchers and programmatic 
 
 119 
decisionmakers, such as is done with the NUHDSS in Nairobi, is important for translating 
research into improved knowledge and implementation for programs. Strategic goals that have 
been framed as ‘Reaching Every District (RED)’ and extending the benefits of vaccination to all 
children, regardless of place, have been helpful for raising awareness about concerns regarding 
the accumulation of under- and non-vaccinated children in communities and the impact it has on 
the dynamics of disease control and overall progress towards expanding the program.24 However, 
there is an over-reliance on survey data from the sub-population with vaccination records 
available to give visualization to issues of timeliness and completion. Although it may not be 
feasible immediately, continued investment in electronic health information systems, including 
capture of immunization and other early child health preventive measures, is needed in the sub-
region.   
 Much of this dissertation focused on describing patterns of vaccination in SSA, 
identifying bottlenecks in delivery, or consideration of disadvantaged groups for prioritized 
targeting in outreach strategies, using data from 2010-2019 across several countries and settings. 
There have been several public health emergencies to occur in the sub-region during this same 
period, but none compare to the current challenges that pandemic spread of SARS-CoV-2 pose 
for immunization services, as well as other mass distribution public health interventions, in the 
sub-region.25 Recent polls from WHO and partners showed substantial disruption in 
immunization services, citing that 89% of program respondents from the WHO African region 
are observing diminished demand due to concerns about the risk of exposure to COVID-19, the 
disease associated with SARS-CoV-2, during vaccination visits in clinical settings, reduced 
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public transport, or stay-at-home orders.26 To date, the burden of excess death due to COVID-19 
in the sub-region is well below the experience of other regions.27 Researchers recently predicted 
that 84 additional childhood deaths (95%CI 14-267) would occur by foregoing immunization 
services for every excess COVID-19 death prevented due to eliminating additional household 
exposure to COVID-19 during routine immunization visits.28 While the benefit of sustaining 
immunization services exceeds the risks by a sizeable amount, each country and sub-national 
jurisdiction will need to weigh the tradeoffs between healthcare worker and family exposures to 
a known risk and the potentially devastating consequences for immunization programs and child 
health associated with increased numbers of under- and non-vaccinated children. As 
opportunities present themselves for healthcare workers to engage with communities, catch-ups 
strategies, especially for outbreak potential VPDs like measles, will need to be prioritized in 
areas that historically have been behind in their vaccination timeliness and completion due to 
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